

1 **Bacille Calmette-Guérin vaccine reprograms human neonatal lipid** 2 **metabolism *in vitro* and *in vivo***

3
4 Joann Diray-Arce^{1,2,16,*}, Asimena Angelidou^{1,2,3}, Kristoffer Jarlov Jensen^{4,5,6}, Maria Giulia
5 Conti^{1,7}, Rachel S. Kelly⁸, Matthew A. Pettengill^{1,9}, Mark Liu¹, Simon D. van Haren^{1,2}, Scott
6 McCulloch¹⁰, Greg Michelloti¹⁰, the EPIC Consortium[#], Tobias Kollmann¹¹, Beate Kampmann¹²,
7 Hanno Steen^{1,2,13}, Al Ozonoff^{1,2}, Jessica Lasky- Su⁸, Christine Stabell Benn^{3,5,14}, Ofer Levy^{1,2,15,*}

8
9 ¹*Precision Vaccines Program*, Division of Infectious Diseases, Boston Children's Hospital,
10 Boston, Massachusetts, 02115, USA;

11 ²Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, 02115, USA;

12 ³Department of Neonatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts,
13 02215, USA;

14 ⁴Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, University of
15 Southern Denmark, 2300, Copenhagen, Denmark;

16 ⁵Bandim Health Project, IN-DEPTH Network, 1004, Bissau, Guinea-Bissau;

17 ⁶Experimental and Translational Immunology, Department of Health Technology, Technical
18 University of Denmark, DK-2800 Kgs Lyngby, Denmark;

19 ⁷Department of Maternal and Child Health, Sapienza University of Rome, 00185, Rome, Italy

20 ⁸Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical
21 School, Boston, Massachusetts, 02115, USA;

22 ⁹Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University,
23 Philadelphia, Pennsylvania, 19107, USA;

24 ¹⁰Metabolon Inc. Morrisville, North Carolina, 27560, USA;

25 ¹¹Telethon Kids Institute, University of Western Australia, Perth, Western Australia, 6009,
26 Australia;

27 ¹²The Vaccine Centre, Faculty of Infectious and Tropical Diseases, London School of Hygiene
28 and Tropical Medicine, London, WC1E 7HT, United Kingdom;

29 ¹³Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, 02115, USA;

30 ¹⁴OPEN, Institute of Clinical Research, University of Southern Denmark, 5000, Odense C,
31 Denmark;

32 ¹⁵Broad Institute of MIT & Harvard, Cambridge, Massachusetts, 02142, USA;

33 ¹⁶Lead contact

34 [#]The Expanded Program on Immunization (EPIC) Consortium

35
36 *Correspondence: joann.arce@childrens.harvard.edu, ofer.levy@childrens.harvard.edu

37 38 **Highlights**

- 39
- 40 • Neonatal BCG immunization generates distinct metabolic shifts *in vivo* and *in vitro*
41 across multiple independent cohorts.
 - 42 • BCG induces prominent changes in concentrations of plasma lysophospholipids (LPLs)
 - 43 • BCG induced changes in plasma lysophosphatidylcholines (LPCs) correlate with BCG
44 effects on TLR agonist- and mycobacterial antigen-induced cytokine responses.
 - 45 • Characterization of vaccine-induced changes in metabolism may define predictive
46 signatures of vaccine responses and inform early life vaccine development.

47 Keywords: BCG vaccines, early life vaccinology, lipidomics, lysophospholipids, metabolomics,
48 newborn immunity, systems vaccinology, vaccines
49

50 **Summary**

51 Vaccines have generally been developed with limited insight into their molecular impact. While
52 systems vaccinology, including metabolomics, enables new characterization of vaccine
53 mechanisms of action, these tools have yet to be applied to infants at high risk of infection and
54 receive the most vaccines. Bacille Calmette-Guérin (BCG) protects infants against disseminated
55 tuberculosis (TB) and TB-unrelated infections via incompletely understood mechanisms. We
56 employed mass spectrometry-based metabolomics of blood plasma to profile BCG-induced
57 infant responses in Guinea Bissau *in vivo* and the U.S. *in vitro*. BCG selectively altered plasma
58 lipid pathways, including lysophospholipids. BCG-induced lysophosphatidylcholines (LPCs)
59 correlated with both TLR agonist- and purified protein derivative (PPD, mycobacterial antigen)-
60 induced blood cytokine production *in vitro*, raising the possibility that LPCs contribute to BCG
61 immunogenicity. Analysis of an independent newborn cohort from The Gambia demonstrated
62 shared vaccine-induced metabolites such as phospholipids and sphingolipids. BCG-induced
63 changes to the plasma lipidome and LPCs may contribute to its immunogenicity and inform the
64 discovery and development of early life vaccines.

65 **Introduction:**

66 Infectious diseases are the leading cause of early life mortality worldwide, with ~2.5
67 million newborns and infants dying from infections each year (World Health, 2020).
68 Approximately 45% of deaths in children under five years of age occurred during the neonatal
69 period, defined as the first 28 days of life (World Health, 2020). Immunization is a cost-effective
70 public health intervention that reduces the risk of morbidity and averts ~2 to 3 million deaths
71 every year. Protective responses to immunization in early life are different from those in older
72 individuals, in part due to the distinct immune system of newborns and young infants (Dowling
73 and Levy, 2014; Sanchez-Schmitz and Levy, 2011). Characterizing sex-, age- and antigen-
74 specific responses is key to developing vaccines tailored for vulnerable populations such as the
75 very young (Whittaker et al., 2018).

76
77 Immunization at birth with live-attenuated *Mycobacterium bovis* vaccines, referred to as
78 Bacille Calmette-Guérin (BCG), is recommended in countries with endemic tuberculosis (TB) to
79 protect infants against miliary TB and tuberculous meningitis (Mangtani et al., 2014). Though
80 there are no definite correlates of protection, some studies have linked BCG efficacy against TB
81 to its ability to effectively induce Th1-polarized neonatal immune responses (Libraty et al., 2014;
82 Marchant et al., 1999). Remarkably, across multiple studies, the administration of BCG in early
83 life has been associated with a reduced incidence of unrelated ("off-target") infections. Such
84 beneficial pathogen-agnostic ("heterologous") effects of BCG are hypothesized to reduce
85 morbidity and mortality far beyond what is expected from prevention of the target disease- i.e.,
86 TB (Higgins et al., 2016). For example, three consecutive randomized trials demonstrated that
87 early administration of BCG to low birth weight newborns in Guinea-Bissau significantly
88 reduced mortality by ~38% (17%-54%) (Biering-Sorensen et al., 2017). BCG pathogen-agnostic
89 effects are still under investigation and may not be evident in all settings (Haahr et al., 2016;
90 Kjaergaard et al., 2016); therefore, identifying high-risk populations may benefit most from BCG
91 vaccination is an active area of research. The rapid beneficial effects of BCG in early life suggest
92 that it may be mediated via innate immunity. The mechanisms mediating BCG protection are
93 under active investigation (Curtis et al., 2020; Moorlag et al., 2019; Zimmermann et al., 2019),
94 with recent evidence suggesting that induction of granulopoiesis may contribute to BCG-induced
95 protection against off-target bacterial infections in early life (Brook et al., 2020).

96
97 One potential mechanism for the heterologous effects of BCG is epigenetic
98 reprogramming of human innate immune cells, i.e., trained immunity, resulting in altered innate
99 immune responses upon rechallenge with heterologous stimuli in adults (Kleinnijenhuis et al.,
100 2012). Systemic metabolic pathways have been implicated in the immune system regulation
101 (Boothby and Rickert, 2017). A potential role for metabolism in the protective effects of BCG
102 has been posited (Kelly and O'Neill, 2015). Training effects may be mediated by metabolites
103 functioning as cofactors for epigenetic enzymes to induce chromatin and DNA modifications;
104 upon rechallenge with a second stimulus that is unrelated to the first stimulus that induces
105 training, trained cells can mount a more rapid and effective immune response (Netea et al.,
106 2016). Changes in glucose, glutamine, and cholesterol metabolism maintain trained immunity
107 through the provision of active intermediate metabolites (Fok et al., 2019). Vaccine-induced
108 metabolic changes that contribute to trained immunity have been studied in adults. Still, the
109 impact of the BCG vaccine on human neonatal metabolism has yet to be characterized
110 (Kollmann, 2013). Given newborns' unique developmental physiology and nutritional/metabolic

111 needs compared to adults, vaccine-induced metabolic changes may be age-dependent (Angelidou
112 et al., 2021; Conti et al., 2020).

113
114 The human metabolome is influenced by physiologic or pathologic states and
115 environmental factors, such as nutrition (Johnson et al., 2016; Playdon et al., 2017), and consists
116 of by-products from signaling cascades. Metabolomics, the study of small molecules associated
117 with physiologic conditions, has been used to identify active or dysregulated pathways (Guijas et
118 al., 2018) in health and disease. Metabolites can define disease phenotypes and are often readily
119 measured and applied to clinical settings (Johnson et al., 2016). Circulating metabolites can have
120 immunomodulatory effects, and, conversely, immune activation can shape the plasma
121 metabolome and predict future disease phenotypes (Diray-Arce et al., 2020; Pettengill et al.,
122 2014). While several metabolites in neonatal monocytes and macrophages such as acetyl-
123 coenzyme A and succinate play a role in the induction of epigenetic modulators, essential to
124 trained immunity, much remains to be learned regarding the distinct neonatal
125 immunometabolism (Arts et al., 2018; Conti et al., 2020; Kan et al., 2018; Reinke et al., 2013).
126 We have recently demonstrated that mass spectrometry-based metabolomics can be applied to
127 newborn plasma samples (Lee et al., 2019), and there is great interest in applying these powerful
128 technologies to characterize neonatal vaccine responses (Amenyogbe et al., 2015; Hagan et al.,
129 2015; Petrick et al., 2019). However, to date, no published systems vaccinology studies have
130 assessed systemic metabolic responses of newborns to immunization.

131
132 In this study, we examined the effects of neonatal BCG vaccination on the global
133 metabolic profile in newborn blood plasma at four weeks of life. Subsequently, we investigated
134 how BCG vaccination impacts the plasma lipidome and both antigen-specific and innate
135 cytokine induction. We report that BCG vaccination induces metabolic shifts *in vivo* and *in vitro*,
136 particularly in lysolipid pathways, including lysophosphatidylcholines (LPCs) that correlate with
137 TLR agonist- and purified protein derivative (PPD, mycobacterial antigen)-induced whole blood
138 cytokine responses. Our observations provide fresh insights into BCG's potential mechanisms of
139 action, identify new candidate pathways and biomarkers that may inform optimization of its
140 beneficial effects, and suggest that vaccine-induced metabolites are relevant to vaccine
141 immunogenicity.

142
143

144 **Results:**
145 **BCG vaccination induced shifts in the infant plasma metabolome**
146

147 To elucidate the impact of early BCG vaccination, plasma samples from *in vivo* and *in*
148 *vitro* cohorts were subjected to comprehensive metabolomics analysis. Our primary *in vivo*
149 cohort consisted of low birthweight newborns from Guinea-Bissau who were enrolled in a
150 randomized clinical trial to receive BCG at birth (classified as early BCG) or at six weeks after
151 birth (delayed BCG) (Biering-Sorensen et al., 2017). In an immunological study nested within
152 the trial, capillary blood samples were collected four weeks after randomization (after BCG was
153 given in the early BCG group and before BCG was given in the delayed BCG group) to
154 investigate the effect of BCG on PPD antigen- and TLR-agonist-induced whole blood cytokine
155 responses *in vitro* (Figure 1A) (Jensen et al., 2015). Catch-up vaccination followed at six weeks
156 of life with Pentavalent vaccine (Penta) and oral polio vaccine (OPV) for the early BCG group
157 and BCG, Penta, and OPV for the delayed BCG group (Figure 2A).
158

159 After the primary analyses (Jensen et al., 2015), blood samples with the remaining
160 plasma of sufficient volume were shipped to the *Precision Vaccines Program* (Boston, MA,
161 USA) for subsequent assays. Study design, including the enrollment and randomization
162 procedures and sample processing of the immunological sub-study, is outlined in Figure S1A-
163 S1C. Characteristics of newborn study participants whose plasma was subjected to metabolomic
164 profiling are described in Table S1.
165

166 Ultrahigh performance liquid chromatography-tandem mass spectroscopy (UPLC-
167 MS/MS) (*Metabolon*; Morrisville, NC, USA) was employed to identify and measure metabolites
168 in the human newborn plasma (Evans et al., 2009). To ensure sufficient plasma volume for this
169 assay, we pooled plasma samples of 10 participants stratified by sex and treatment prior to mass
170 spectrometry analysis. Mass spectrometry peaks were identified based on their corresponding
171 retention time/index (RI), mass to charge ratio (m/z), and chromatographic data compared with
172 *Metabolon's* library of purified standards or recurrent unknown entities. To reduce the
173 dimensionality of the data and identify the discriminative overview of the metabolomes
174 classified by grouping, we conducted a supervised sparse Partial Least Square Discriminant
175 Analysis (sPLS-DA). We extracted two components, Component 1 (Comp 1) and Component 2
176 (Comp 2), which accounted for 15% and 11% of the variation, respectively (Figure 2B). The first
177 two components elucidated distinct clustering between delayed BCG and early BCG, suggesting
178 that early BCG immunization induced shifts in the plasma metabolome. The top 30 loadings
179 identified metabolites associated with early BCG (orange) and delayed BCG (blue), including
180 several glycerophospholipids (GPCs), increased in the early BCG group (Figure 2C).
181

182 Of the 674 metabolites detected, 623 passed quality control and assurance. We focused
183 on endogenous biochemicals in which 544 metabolites were included in the analysis (Figure
184 S2A-E). Among these metabolites, 55 biochemicals (10.11%) demonstrated significantly
185 differential abundance between the early vs. delayed BCG newborn groups ($\alpha=0.05$) (Table
186 S2, Figure 2E). A majority of significant metabolites belonged to the lipid superclass.
187 Unsupervised hierarchical clustering of differentially abundant metabolites (DAMs) illustrated
188 higher levels of lipid metabolites in the early BCG compared to the delayed BCG group. In

189 contrast, early vs. late BCG administration was associated with lower plasma amino acid
190 concentrations (Figure 2D).

191

192 **BCG induced prominent shifts in plasma lipid pathways**

193 Compared to the delayed BCG group, early BCG administration was associated with
194 distinct concentrations of a range of lipid pathways and metabolites. Of note, greater than half of
195 the metabolites whose levels changed significantly ($p < 0.05$) between the groups belonged to the
196 lipid superclass (Figure 3A), and 39% of DAMs were of the lysophospholipid (LPL) subclass
197 (Figure 3A). Early BCG administration was consistently associated with robust production of
198 selected sphingolipid, monoacylglycerol, steroid, and LPL metabolites (Table S2). In contrast,
199 palmitoylglycerols and pregnanediol disulfate (progesterin steroids) were decreased in the early vs.
200 delayed BCG group (Figure 3B, Table S2).

201

202 We used pathway-based network reconstruction (implementation: *Metscape* plugin of
203 *Cytoscape*) to construct a compound network providing a comprehensive overview of metabolic
204 signatures to compare early vs. delayed BCG newborn groups (Figure 3C). As BCG
205 administration at birth was associated with high production of lipid metabolites, our network
206 demonstrated that glycerolipid pathways were interrelated and shared common nodes with other
207 metabolic pathways (e.g., bile acid biosynthesis, galactose glycerophospholipid,
208 glycosphingolipid, and linoleate metabolism). In addition, we utilized metabolite set enrichment
209 analysis (MSEA), which takes into account the quantitative measurement of each metabolite and
210 groups them into functionally related sets from a collection of predefined human metabolic
211 pathways (Jia et al., 2014). Results from MSEA were consistent with observations from network
212 reconstruction, suggesting a prominent role for lipids upon early BCG vaccination in newborns
213 (Figure 3C, Table S3). Early BCG administration was associated with increased production of
214 multiple metabolites of the glycosphingolipid and glycerophospholipids, including LPCs. In
215 contrast, glycerol, phosphoethanolamines, and cortisol were decreased in the early vs. delayed
216 BCG group.

217

218 To gain further insight into the effects of BCG on the infant plasma lipidome, we assayed
219 the same *in vivo* samples (i.e., those characterized using the untargeted metabolomics platform)
220 using Complex Lipid Panel LC-MS/MS-based lipidomics (Figure 4A). Across the 14 lipid
221 classes identified by this assay, we identified a total of 963 lipids, with triacylglycerol (TAG)
222 being the most abundant lipid subclass, followed by phosphatidylethanolamines (PEs) and
223 phosphatidylcholine (Figure 4B). Separation of groups by the timing of BCG vaccination (early
224 vs. delayed) accounted for 52% variance at Comp 1 and 15% at Comp 2 (Figure 4C). A total of
225 30 lipids (3.1%) were significantly perturbed, comparing early vs. delayed BCG newborns
226 (Figure 4D). Four free fatty acid components (FFA 20:0, 22:2, 22:4, 24:0) demonstrated
227 increased concentration in the early BCG group. Early BCG administration was associated with
228 decreased concentrations of most LPC metabolites except LPC (22:2), which was significantly
229 increased. BCG immunization was associated with lower plasma concentrations of multiple lipid
230 sub-pathway families, including lysophosphatidylethanolamines (LPEs 18:2, 20:3, 20:4, 22:4),
231 monoacylglycerols (MAGs 12:0, 14:0, 16:0, 16:1, 18:1, 18:2, 18:3, 22:5, 22:6), phosphocholines
232 (PCs 14:0/16:1 and 16:0/22:2), PEs (18:0/22:2, 18:1/22:0, and 18:2/16:1) and TAGs (TAG44:0-
233 FA18:0, TAG53:5-FA18:3, and TAG56:6/FA22:4) (Table S4).

234

235 **BCG induced metabolic signatures *in vitro* mirror those induced by early BCG vaccination**
236 ***in vivo***

237
238 We hypothesized that BCG-induced metabolic signatures detected *in vivo* could be
239 modeled *in vitro*. To this end, we obtained human cord blood from a Boston newborn cohort
240 (full-term newborns delivered via cesarean section) and assessed responses utilizing a whole
241 blood assay (WBA) (Figure 1B) (Angelidou et al., 2020a). The WBA features multiple
242 advantages, including (a) utilization of small volumes of minimally perturbed primary
243 leukocytes, (b) the presence of autologous plasma, a rich source of age-specific
244 immunomodulatory components (e.g., maternal antibodies, adenosine, etc.) (Pettengill et al.,
245 2014), and (c) the ability to model and analyze responses of each participant to multiple
246 conditions such as vehicle control and BCG-stimulation. WBA-derived supernatants (90%
247 plasma v/v) were subjected to high-throughput metabolomics and complex lipid panel lipidomics
248 (WBA; Figures S1B and 1B). Untargeted metabolomics detected 568 metabolites and analyzed
249 437 metabolites after quality control and assurance and filtering out the xenobiotics to focus on
250 endogenous metabolites (Figure S2F-J). BCG-only samples (i.e., no blood) at low and high
251 dilution were also assayed as additional controls to assess background and identify metabolites
252 produced by the BCG vaccine itself (Figure S3A). BCG-only controls demonstrated lower
253 measurable concentrations in most lipid families (Figure S3B). Also, they had a lower number of
254 detected lipids (Figure S3C) compared to cord blood stimulated with vehicle or with BCG.
255 Matched pairs or pairwise comparisons of samples from the same participant were used for
256 analysis.

257
258 Principal component analysis (PCA) of metabolites detected in plasma from the *in vitro*
259 stimulation assay illustrated that BCG treatment induced changes in the plasma metabolome
260 (Figure 5A). Hierarchical clustering demonstrated the grouping of metabolite levels by treatment
261 (Figure 5B). Metabolite set enrichment analysis (MSEA) using relative metabolite
262 concentrations from the Boston *in vitro* cohort identified the glucose-alanine cycle, lactose
263 degradation pathway, and sphingolipid metabolism as the top enriched pathways after BCG
264 stimulation (Figure 5C). Metabolites that significantly differed between BCG-stimulated vs.
265 control conditions *in vitro* included 25 upregulated metabolites and 77 down-regulated
266 metabolites (Figure 5D, Table S5). A comparison between the *in vivo* Guinea Bissau and the *in*
267 *vitro* Boston cohorts revealed 47 shared enriched metabolic pathways, representing a 58%
268 overlap (Figure 7A). The number of unique pathways identified in BCG-stimulated samples *in*
269 *vitro* (19 pathways: 23.5%) was slightly higher than that in the early BCG group *in vivo* (15
270 pathways: 18.5%) (Figure 7A). Our results suggest more acute metabolic changes detected *in*
271 *vitro* (18 hr post-BCG stimulation) than four weeks post *in vivo* BCG vaccination.

272
273 Lipidomic analysis of supernatants from whole blood stimulated with BCG *in vitro*
274 identified 963 lipids belonging to 15 families. Among those, only 75 lipids (7.6%) were
275 significantly perturbed, with most lipids decreased upon BCG stimulation (Figure 4E). BCG
276 stimulation induced a decrease of several plasma phospholipids metabolism intermediates, such
277 as choline phosphate, glycerophosphocholine (GPC), and phosphoethanolamine (PE) (Table S7).
278 Similar to total metabolic changes, more acute differences were noted for lipids stimulated *in*
279 *vitro* (18 hr stim) compared to *in vivo* (4 weeks post-vaccine), possibly reflecting differences in
280 the kinetics of BCG-induced lipid changes (Figure 4F). Multiple LPC components (LPC 16:0,

281 18:2, 20:4, 22:6) and other lipids were also decreased in BCG-stimulated samples *in vitro*
282 (Figure 4G).

283
284 Previous studies have assessed the role of fatty acids and the eicosanoid pathway in Mtb
285 infection and BCG vaccine efficacy (McFarland et al., 2008). Eicosanoids are a family of lipid
286 mediators involved in inflammation (Figure S3F). Prostaglandin E₂ (PGE₂) was significantly
287 increased upon BCG stimulation (Figure S3D), while we observed a significant reduction in
288 docosahexaenoic acid (DHA 22:6 (n-3)) (Figure S3E) in BCG-stimulated samples vs. control.
289 Linoleic acid (FFA 18:2) and arachidonic acid (FFA (20:4)), an immediate precursor of PGE₂
290 (Figure S3G-H), were both decreased in BCG-stimulated samples compared to control. PGs were
291 not detected in the Guinea-Bissau *in vivo* cohort (Table S2). However, the time points were
292 markedly different – i.e., 4 weeks after BCG *in vivo* vs. 18 hours *in vitro*, suggesting an acute
293 inflammatory role for PGs rather than a contribution to a prolonged metabolic response.

294
295 **BCG-induced plasma lysophospholipids *in vivo* at 4 weeks post-vaccination correlated with**
296 ***in vitro* TLR agonist and mycobacterial antigen-induced cytokine/chemokine responses**

297
298 Lysophosphatidylcholine (LPC) is a critical component of low-density lipoprotein, and
299 high LPC levels have been associated with various diseases (Law et al., 2019; Okita et al., 1997).
300 LPC modulates immune responses by controlling distribution, trafficking, and activation of
301 leukocytes (Chiurchiù et al., 2018) and is a candidate sepsis treatment (Yan et al., 2004). In our
302 study, early BCG vaccination perturbed levels of several LPC components 4 weeks post-
303 vaccination *in vivo* (Figure 6A-F). Early BCG administration was associated with significantly
304 increased plasma concentrations of LPC16:0 and LPC18:0 and decreased concentrations of
305 LPC18:2, -20:3, -20:4 and -22:6.

306
307 The immunogenicity of BCG in the Guinea-Bissau *in vivo* cohort, as measured by whole
308 blood cytokine responses to PPD antigen and TLR-agonist stimulation, has been previously
309 reported (Jensen et al., 2015). To study the relationship between BCG-induced LPLs *in vivo*
310 and recall cytokine production *in vitro*, we analyzed previously generated cytokine
311 measurements on PPD and other TLR agonist recall responses for the subset of newborn
312 participants included in our metabolomic and lipidomic studies. Relative to the delayed BCG
313 cohort, newborns who received early BCG demonstrated increased PPD-induced production of
314 TNF α (p=0.0072), IL5 (p<0.0001), IL6 (p=0.0229), IL17 (p<0.0001), and IFN γ (p<0.0001)
315 (Figure S4A-G, Table S6). Significant correlations were noted between concentrations of LPC
316 species (LPC 14:0, 16:0, 17:0, 18:0, 18:1, 18:2, 20:1, 20:2, 20:4) and cytokines IL5, IL6, IL10,
317 TNF α , IL17 and IFN γ (Figure 6G-H). Multiple LPCs (LPC 22:5, 17:0, 16:1, 15:0) positively
318 correlated with TLR4- and TLR7/8-mediated IL6 production, while LPCs 20:1, 20:0, 18:0 and
319 16:0 negatively correlated with TLR2/1-mediated IL6 production. Multiple LPCs (LPCs 20:4,
320 20:0, 19:1, 17:0, 14:0) also positively correlated with TLR2/1-, TLR7/8-mediated as well as
321 PPD-induced IL10 production. In particular, LPC 18:0 was positively correlated with PPD-
322 induced IL10 production. These observations raise the possibility that alterations in LPLs, lipids
323 with known roles in immune regulation and responses to mycobacterial infection (Lee et al.,
324 2018), may contribute to BCG immunogenicity.

325

326 To determine the response to stimulation with BCG *in vitro*, we subjected WBA
327 supernatants to multiplex cytokine and chemokine profiling (Figures S1B and 1B). BCG
328 stimulation of cord blood for 18 hr significantly induced the production of multiple cytokines
329 and chemokines, resulting in a balanced Th1-, Th2-, and Th17-polarizing cytokine profile
330 (Figure S5A). Consistent with previously reported acute activation of BCG-induced Th1
331 responses (Angelidou et al., 2020a) and early proinflammatory bias (Freyne et al., 2018), the
332 addition of BCG to whole blood *in vitro* induced IL-1 β , a cytokine that may be important to
333 BCG vaccine immunogenicity (Scheid et al., 2018) and innate training that may contribute to
334 non-specific/pathogen-agnostic beneficial effects (Arts et al., 2018) (Figure S5B). BCG also
335 induced the production of anti-inflammatory IL-10 (Figure S5B). As expected, these plasma
336 cytokines were not detected *in vivo* at the 4-week time point, given likely normalization to
337 baseline 4-weeks after vaccination (Stenken and Poschenrieder, 2015).

338 339 **Comparison of BCG-induced metabolic profiles across cohorts demonstrates modulation of** 340 **common metabolomic pathways**

341
342 To validate metabolomic signatures of the BCG vaccine in early life, we compared the
343 Guinea-Bissau and Boston cohorts with another independent newborn group from the EPIC-001
344 study in The Gambia (West Africa) using high-throughput metabolomics. Newborns (n=27) were
345 assigned to either receive the Expanded Program on Immunization (EPI) vaccines (OPV, BCG,
346 and HBV) at birth or delayed during the first week of life to study the effect of vaccine responses
347 on early life immune ontogeny (Figure 1C, Figure S1C) (Lee et al., 2019). Peripheral blood was
348 collected at two time points: a pre-vaccination sample at the day of life 0 (DOL0; birth), then a
349 second sample randomized at either DOL1, DOL3, DOL7. All enriched metabolite sets
350 discovered in the EPI-vaccinated Gambia cohort were shared among the Guinea-Bissau and
351 Boston cohorts suggesting that BCG-induced metabolic pathways followed a consistent pattern
352 (Figure 7A, 7C, 7D). Shared sets of BCG-induced metabolic changes included sphingolipid
353 metabolism, glycine and serine metabolism, methionine metabolism, purine metabolism,
354 galactose metabolism, bile acid biosynthesis, amino sugar metabolism, lactose synthesis,
355 spermidine and spermine biosynthesis, and betaine metabolism (Figure 7D). The variety and
356 abundance of such BCG-modulated pathways are consistent with newborns' complex metabolic
357 and bioenergetic needs. LPLs belonging to phospholipid biosynthesis metabolite enriched sets
358 demonstrated perturbation across all three cohorts. While a more significant number of
359 downregulated metabolites were noted following BCG-stimulation *in vitro*, both West African *in*
360 *vivo* cohorts (Guinea Bissau and The Gambia) displayed similar metabolic trends, suggesting
361 similar metabolome profiles within this geographic region (i.e., West Africa; Figure 7B). Of
362 note, ~70% of significant metabolites in Gambian neonates belonged to the lipid class (Table
363 S8), supporting a major lipid signature of BCG vaccination early in life.

364
365
366

367 Discussion

368

369 Herein we present the first characterization of BCG-induced changes to the human
370 newborn plasma metabolome. Prior studies of the neonatal plasma metabolome have used
371 umbilical cord blood for metabolomic profiling (Fanos et al., 2013; Mussap et al., 2013) due to
372 limitations in the number and quantity of neonatal blood draws. To our knowledge, the sole
373 exception is our prior study of immune ontogeny that assessed plasma metabolites from the
374 human peripheral newborn blood plasma (Lee et al., 2019). Herein, we employed plasma
375 metabolomics to define BCG-induced metabolic changes in three independent newborn cohorts,
376 two *in vivo* (Guinea Bissau and The Gambia; West Africa) and one *in vitro* (Boston, MA: USA).
377 To our knowledge, our effort represents the first application of metabolomics to characterize
378 vaccine action in newborns, who exhibit distinct immunity and are at the greatest risk of
379 infection (Whittaker et al., 2018).

380

381 Human *in vitro* assays are a promising approach to characterize vaccine action and
382 generate data with relevance *in vivo* (Dowling and Levy, 2014; Sanchez-Schmitz et al., 2018).
383 Using a whole blood stimulation assay, we were able to recapitulate metabolic changes induced
384 by early BCG vaccination and identify additional candidate biomarkers of early BCG
385 immunization in newborns. Systems vaccinology studies have demonstrated overlap between
386 vaccine-induced systems biology signatures *in vivo* and those detected by WBA *in vitro* (Diray-
387 Arce et al., 2021; Lee et al., 2019; Li et al., 2017; Nakaya et al., 2016; Nakaya et al., 2011; White
388 et al., 2012). A recent study assessed the impact of neonatal BCG administration on clinical
389 outcomes and epigenetic and cytokine responses in peripheral blood mononuclear cells
390 (PBMCs). Still, it did not examine metabolomic signatures (Prentice et al., 2021). Neonates
391 typically exhibit Th2-polarized immune responses (Dela Pena-Ponce et al., 2017), but the live
392 attenuated BCG vaccine engages multiple PRRs and induces balanced Th1/Th2 responses in the
393 early life (Marchant et al., 1999; Sanchez-Schmitz et al., 2018). Given the vital role of
394 metabolism in immunity and the unique metabolic state of newborns, we sought to explore how
395 BCG given at birth affects the newborn plasma metabolome. We showed that neonatal BCG
396 vaccination perturbs plasma lipid pathways in a reproducible pattern. Interestingly, metabolic
397 changes correlated with *in vitro* cytokine and chemokine responses of whole blood to innate
398 (TLR agonist) and adaptive (PPD antigen) stimuli.

399

400 A remarkable feature of our results is that early administration of BCG appeared to re-
401 model the plasma lipidome, shifting concentrations of LPLs such as LPCs and GPCs. LPCs are
402 quickly metabolized by lysophospholipases to GPCs, which could explain our observation of
403 decreasing plasma LPCs and increasing GPCs in our early BCG dataset (Figure 2C and 4G).
404 Interestingly, a consistent decrease in plasma GPCs has been observed in sepsis vs. non-infected
405 patients with systemic inflammatory response syndrome (SIRS)(Langley et al., 2013) while
406 exogenous stearyl-GPC improved sepsis outcomes in mice (Yan et al., 2004). Our results thus
407 raise the possibility that BCG-induced increases plasma GPCs may contribute to pathogen-
408 agnostic protection against sepsis and respiratory infections in early life.

409

410 Lipid metabolism is key to cell membrane structure and function, including in that of
411 leukocytes (Lochner et al., 2015), and has been proposed to contribute to vaccine-induced
412 epigenetic reprogramming of immune responses (Netea et al., 2016; O'Neill et al., 2016). We

413 noted that BCG immunization induced a decrease in plasma concentrations of most of the LPLs
414 detected. These findings were validated in our *in vitro* assay. Prominent among the plasma LPLs
415 whose concentrations changed after BCG administration were LPCs. Bioactive products of
416 phospholipase-mediated removal of fatty acids from phosphatidylcholine, LPCs are plasma
417 constituents that can act directly on cell membranes and signal via protein G protein-coupled
418 receptors or TLRs (Sharma et al., 2020), thereby exerting a range of immunologic effects
419 (Knuplez and Marsche, 2020; Sharma et al., 2020). LPCs such as LPC 18:1 and 16:0 can
420 modulate neutrophil reactive oxygen production (Ojala et al., 2007), promote TLR signaling,
421 enhance the generation of mature dendritic cells (DCs) from differentiating human monocytes as
422 well as enhance antigen-specific cytotoxic T cell and antibody responses *in vivo* (Knuplez and
423 Marsche, 2020; Perrin-Cocon et al., 2006). At baseline, newborn plasma contains relatively high
424 concentrations of LPC (20:4) and PC (36:4), but the plasma phospholipid profile changes
425 markedly over time in a manner dependent on the dietary fatty acid composition (Uhl et al.,
426 2016).

427
428 In our study, BCG-induced changes in LPCs correlated with blood cytokine responses to
429 stimulation with multiple TLR agonists and mycobacterial antigen (PPD) (Figure 6G-6H).
430 Interestingly, potential pro-inflammatory effects of BCG vaccination may be counterbalanced by
431 enhanced production of LPC 16:0, an LPC that was increased in our *in vivo* cohort (Figure 6A).
432 LPC 16:0 can act as an "eat-me" signaling target, enhancing uptake of apoptotic cells (Soehnlein
433 et al., 2009), as well as regulating the production of TNF and nitric oxide (NO) (Yan et al.,
434 2004). The kinetics of BCG-induced LPC 16:0 production remains to be defined, but to the
435 extent that our *in vitro* studies reflect kinetics *in vivo*, they may not initiate until after the first
436 day of vaccination. LPC can function as a dual-activity ligand molecule triggering a classical
437 proinflammatory phenotype by activating TLR4 and TLR2/1 mediated signaling on human
438 embryonic cells (Carneiro et al., 2013). LPC species are also regulators of the innate immune
439 response preventing excess inflammation and limiting mycobacterial survival in the host (Lee et
440 al., 2018). Dual immunologic roles of LPCs have also been observed in mice wherein LPC
441 increased production of antimicrobial agents ROS and NO while inducing IL10 in Mtb-infected
442 macrophages, thereby enhancing macrophage-based host defense while avoiding excessive
443 production of pro-inflammatory cytokines (Lee et al., 2018). Of note, LPCs have been explored
444 as novel immunomodulatory agents. Indeed, systemic administration of LPC protected mice
445 against experimental sepsis-induced lethality, enhanced clearance of bacteria, and inhibited the
446 production of pro-inflammatory cytokines TNF α and IL1 β (Lee et al., 2018). Overall, BCG
447 modulation of plasma LPCs may fine-tune immune responses to shape cellular immunity to BCG
448 antigens, enhance antimicrobial activity and avoid anti-inflammatory responses.

449
450 In addition to our observations regarding BCG-induced changes in LPCs, BCG uptake by
451 the host can trigger several other lipid pathways, such as PGE₂ production from the eicosanoids
452 (Almeida et al., 2009). Eicosanoids regulate macrophage death and participate in several cellular
453 pathways that either promote or inhibit inflammation (Behar et al., 2010). PGE₂ induces
454 apoptosis of infected macrophages, a process that triggers the activation of DCs and subsequent
455 enhancement of T cell responses crucial for optimal vaccine effectiveness and protection (Behar
456 et al., 2010). In stark contrast to BCG (*M. bovis*) and attenuated Mtb strains, virulent Mtb strains
457 are weaker PGE₂ inducers and induce necrosis of infected macrophages, enabling innate immune
458 evasion and delay in initiation of adaptive immunity (Behar et al., 2010; Chen et al., 2008).

459 Upon stimulation of human newborn blood with BCG *in vitro*, we noted a significant increase in
460 PGE₂ and arachidonate acid (FFA (20:4)), an immediate precursor of prostaglandin E₂ (PGE₂).
461 Possibly due to their short half-life, PGs were not detected 4 weeks after BCG immunization in
462 the Guinea-Bissau *in vivo* cohort.

463
464 Differences in FFA composition between conditions (BCG stimulated vs. control) for
465 both our *in vivo* and *in vitro* cohorts were consistent with previous studies suggesting vaccine-
466 induced alterations in membrane remodeling and lipid metabolism (Diray-Arce et al., 2020; Li et
467 al., 2017). Alternatively, they may reflect nutritional differences or represent the distinct
468 metabolic needs of the newborn between DOL0 when cord blood was obtained for the *in vitro*
469 assay and DOL28, the time point at which peripheral blood was collected from the *in vivo* cohort
470 (Conti et al., 2020).

471
472 Vaccine interactions are increasingly recognized in systems vaccinology, and a growing
473 body of literature suggests that the nature of the vaccine stimulus (live attenuated vs. killed or
474 inactivated), as well as the order in which vaccines are administered, matters for their net off-
475 target effects (Blok et al., 2020; Clipet-Jensen et al., 2021; Higgins et al., 2016; Li et al., 2020;
476 Sorup et al., 2016; Thysen et al., 2019; Welaga et al., 2017). In our cohort, early BCG was given
477 together with OPV, another live attenuated vaccine given at birth in developing countries, shown
478 to confer mortality benefits from infectious causes (Andersen et al., 2018; Lund et al., 2015).
479 Even though BCG and OPV could not be studied separately, analysis of the parent trial with
480 complete follow-up vs. after censoring for national OPV campaigns yielded similar mortality
481 benefits for the early BCG (Biering-Sorensen et al., 2017). Delayed BCG was given with OPV
482 and Penta, a combination of inactivated vaccines including DTP, per the GB national
483 immunization schedule. Studies comparing the clinical and immunologic effects of different
484 sequences of vaccines are needed to assess the off-target effects of EPI vaccinations, avoid any
485 undesirable negative effects on mortality and fully leverage beneficial pathogen-agnostic effects
486 for clinical benefit.

487
488 BCG strain differences may also partially account for some differences observed between
489 the *in vitro* (BCG-Tice) and *in vivo* (BCG-SSI) cohorts (Angelidou et al., 2020b). However, the
490 effect of BCG on LPL plasma concentrations was similar (consistent decrease both *in vivo* and *in*
491 *vitro*) regardless of strain. Even though our study was not specifically designed to address BCG
492 strain differences, future studies should make an effort to incorporate *in vitro* testing of BCG
493 strains administered *in vivo*. In addition, human vaccine trials testing BCG-induced pathogen-
494 specific and -agnostic protection should adopt study designs amenable to head-to-head strain
495 comparisons in order to detect actionable differences in vaccine efficacy and immune signatures
496 (Comstock, 1988).

497
498 Our study features a number of strengths, including (a) a focus on human immune
499 responses to BCG, one of the most commonly given vaccines across the globe that is critical to
500 newborn health and is also being studied for potential benefits in protecting against viral
501 infection and auto-immune diseases (Arts et al., 2018; Diray-Arce et al., 2020; Faustman, 2020;
502 Moorlag et al., 2020); (b) novel application of state-of-the-art plasma metabolomic and lipidomic
503 technologies to characterize BCG responses in vulnerable newborn cohorts in low income
504 settings (West Africa); (c) study of multiple independent cohorts *in vivo* and *in vitro*; (d)

505 identification of lipids and in particular LPLs/LPCs as key metabolites altered by BCG; (e)
506 significant correlation of LPCs with innate (TLR agonist) and adaptive (PPD) cytokine
507 responses; and (f) validation of BCG-induced metabolic signatures across three independent
508 cohorts in West Africa (Guinea Bissau and The Gambia; *in vivo*) and North America (Boston,
509 USA; *in vitro*). Overall, by demonstrating the applicability of metabolomics in vulnerable
510 newborns from resource-poor settings and defining novel candidate biomarkers that may
511 contribute to BCG's protective effects, our study represents an important advance in the field of
512 neonatal systems vaccinology.

513
514 Our study also has several limitations, including (a) limited blood sample volumes from
515 newborns necessitating pooling of samples by sex and treatment prior to metabolomic and
516 lipidomic analyses, (b) a relatively high neonatal mortality in the early BCG trial so that some
517 selection bias may have occurred, as we were only able to assess those who survived to 4 weeks
518 of age, and (c) a possibility for false-positive findings for the Guinea-Bissau samples, as we
519 chose not to adjust for multiple comparisons (Rothman, 1990). Regarding the latter, many false
520 discovery rate (FDR) methods are considered too stringent for metabolomics analysis due to the
521 high correlation and redundancy between metabolite features, resulting in a lack of agreed-upon
522 standards in the field. We mitigated FDR concerns by validating our findings using a human
523 newborn *in vitro* system and cross-comparison with a second independent Gambian newborn
524 cohort studied *in vivo* to model BCG-induced metabolic shifts. Finally, BCG may induce a wider
525 variety of metabolic pathways, and future studies are required to identify their significance and
526 functional relation to immunogenicity and protection, as well as their correlation with other
527 systems biology ("omic") measures such as systems serology (Ackerman et al., 2017).

528
529 In summary, we have demonstrated the feasibility of assessing neonatal plasma
530 metabolites in a resource-poor setting to identify vaccine-induced metabolic pathways in this
531 study. BCG-induced alterations in LPLs, especially LPCs known to have roles in immune
532 regulation and response to infection (Carneiro et al., 2013), were particularly pronounced and
533 correlated with innate (TLR agonist) and adaptive (PPD) cytokine responses, suggesting that
534 LPCs may contribute to BCG immunogenicity. These lipid biomarkers are novel candidates for
535 correlates of protection that may contribute to BCG's specific (vs. TB) and heterologous
536 protective effects. Overall, our study suggests that vaccine-induced metabolites, and especially
537 lipids, may be relevant biomarkers of vaccine immunogenicity that may help inform more
538 precise discovery and development of vaccines.

539
540
541

542 **STAR Methods**

- 543 • **KEY RESOURCES TABLE**
- 544 • **CONTACT FOR REAGENT AND RESOURCE SHARING**
- 545 • **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- 546 ○ **Newborn cohort characteristics and sample preparation**
- 547 ▪ Guinea-Bissau *in vivo* infant cohort receiving BCG at birth or delayed.
- 548 ▪ Boston newborn cohort stimulated *in vitro* with BCG or saline control.
- 549 ▪ Gambian *in vivo* cohort receiving EPI vaccines (BCG, HBV, OPV) at
- 550 birth or delayed
- 551 • **METHOD DETAILS**
- 552 ○ **Global Untargeted Metabolomics Profiling**
- 553 ○ **Complex Lipid Platform Lipidomics**
- 554 ○ ***In vitro* stimulation of blood derived from early- vs. delayed-BCG infants**
- 555 **with TLR agonists and mycobacterial antigen purified protein derivative**
- 556 **(PPD) to assess cytokine responses**
- 557 • **QUANTIFICATION AND STATISTICAL ANALYSIS**

558

559

560 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Chemicals, Peptides and Recombinant Proteins		
Bacille Calmette-Guérin Vaccine (BCG)	Statens Serum Institute, Copenhagen, Denmark	Strain 1331
	Merck, USA	TICE
Hepatitis B Vaccine (HBV)	Recombivax	NDC#: 0006-4981-00
Lipopolysaccharide (LPS)	Sigma-Aldrich	From E. coli serotype
Phosphate Buffered Saline (PBS)	Gibco, Life Technologies	Cat#: 10010023
Roswell Park Memorial Institute (RPMI) medium	Gibco, Life Technologies Europe BV	RPMI-1640 void of L-Glutamine
Sodium pyruvate (Na-pyruvate)	Lonza, Copenhagen, Denmark	Cat#: 13-115E
L-Glutamine-Penicillin-Streptomycin	Gibco, Life Technologies	Cat#: 10378016
Purified protein derivative (PPD)	Statens Serum Institute, Copenhagen, Denmark	From M. tuberculosis Tuberculin PPD RT23 “SSI”
Adenosine deaminase assay kit	Diazyme Laboratories, Poway, CA	Cat#: DZ117A-K
Lysophosphatidylcholine (LPC) kit	MyBioSource	Cat#: MBS2700657
TLR 7/8 agonist	Invivogen	R848 (Resiquimod) Cat#: tlr1-r848
Methanol	Applied Biosystems, ThermoFisher	Cat#: 400470
Ammonium acetate	Invitrogen	Cat#: AM9070G
Dichloromethane	Applied Biosystems, ThermoFisher	Cat #: 402152
Luminex Kit	Invitrogen/Life Technologies, Carlsbad, CA	Consists of 41 analytes including Th1-, Th2-, and Th17- cytokines,

		chemokines and hematopoietic factors
Deposited Data		
	ImmPort	SDY1709, SDY1256
Experimental Model: Organisms/Strains	HMDB	Version 5.0
Software		
GraphPad Prism	Graphpad Software	
R	https://www.r-project.org	3.5.1 Feather Spray
R studio	https://www.rstudio.com/	1.1.463
RFmarkerdetector	https://cran.r-project.org/web/packages/RFmarkerDetector/RFmarkerDetector.pdf	1.0.1
e1071	https://cran.r-project.org/web/packages/e1071/index.html	1.7-0
dplyr	https://cran.r-project.org/web/packages/dplyr/dplyr.pdf	0.7.8
plyr	https://cran.r-project.org/web/packages/plyr/plyr.pdf	1.8.4
RcolorBrewer	https://cran.r-project.org/web/packages/RColorBrewer/index.html	1.1-2
ggplot2	https://cran.r-project.org/web/packages/ggplot2/ggplot2.pdf	3.1.0
ggrepel	https://cran.r-project.org/web/packages/ggrepel/index.html	0.8.0
ggfortify	https://cran.r-project.org/web/packages/ggfortify/index.html	0.4.5
stringr	https://cran.r-project.org/web/packages/stringr/stringr.pdf	1.3.1
WGCNA	https://cran.r-project.org/web/packages/WGCNA/index.html	1.66
mixOmics	https://cran.r-project.org/web/packages/mixOmics/index.html	6.3.2

561
562
563
564

CONTACT FOR REAGENT AND RESOURCE SHARING

565 Requests for information regarding reagents and resources should be directed to and will be
566 fulfilled by correspondence to Dr. Ofer Levy MD, Ph.D., Director of the *Precision Vaccines*
567 *Program* at Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
568 (ofer.levy@childrens.harvard.edu).

569

570 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

571 **Newborn cohort characteristics and sample preparation**

572 *Guinea-Bissau study of infants receiving BCG at birth or delayed.* A randomized-controlled trial
573 (RCT) of early BCG vaccination in low birth weight (<2.5 kg) neonates was conducted by the
574 Bandim Health Project (BHP) in Guinea-Bissau, West Africa, with neonatal mortality as the
575 primary outcome. A sub-group of the infants participating in the RCT was invited to participate
576 in an immunological study during 2011-2012 to assess the effect of early BCG vaccination on *ex*
577 *vivo* cytokine responses to PPD and innate agonists. Previous publications have described the
578 details of the enrollment and randomization procedures of the RCT (Biering-Sorensen et al.,
579 2017) and the blood collections and sample processing of the immunological sub-group study
580 (Jensen et al., 2015). In brief, newborns eligible for participation in the RCT were low birth
581 weight (<2500 g), not overtly ill, had not received BCG, and had no malformations at the time of
582 enrollment. Informed consent was obtained from the mothers of the recruited newborns. The
583 BCG RCT and the immunological sub-study were approved by the National Committee on
584 Health Ethics of the Ministry of Health in Guinea-Bissau, and a consultative approving statement
585 was obtained from the Danish National Committee on Biomedical Research Ethics. The BCG
586 trial was registered with clinicaltrials.gov, number NCT00625482. Details are illustrated in Fig
587 S1.

588

589 Upon enrollment, the infants were randomized (1:1) to an infant dose of BCG-SSI
590 (Statens Serum Institut, SSI; Copenhagen, Denmark) or delayed BCG immunization at six
591 weeks. Infants assigned to early BCG were vaccinated intra-dermally in the upper deltoid region
592 with 0.05 ml BCG vaccine (strain 1331, SSI, Copenhagen, Denmark) by trained nurses. Infants
593 assigned to the control group were treated according to local practice such that vaccination was
594 postponed until they reached >2.5 kg in weight, or more commonly when they presented for their
595 first Penta vaccine (DTP-HBV-Hib) recommended at six weeks of age. The Pentavalent vaccine
596 given to infants was either *Easyfive* (Panacea Biotech India), *Quinvaxem* (Berna Biotech Korea
597 Corp) or *Pentavac* (Serum Institute of India) for this randomized control study. All infants
598 received oral polio vaccine (OPV) at birth. For enrollment into the immunological sub-group
599 study, infants were visited at home by the study team four weeks after randomization to BCG or
600 no BCG. For logistical reasons, infants living in Bissau City and nearby suburbs were given
601 priority. After providing informed consent, the mother was interviewed about the health status of
602 her child, and the length, weight, and mid-upper arm circumference of the child were measured.
603 Clinical data on sex, weight, BCG scar, PPD testing results were also available. Scar size was
604 defined as the average of two perpendicular diameters on the scar formed at the injection site.
605 Local reaction to the BCG vaccine was assessed and measured. Blood was collected by heel
606 puncture into a heparin-coated tube.

607

608 For this current study, we included plasma samples from newborns randomized within
609 the first week of life. However, samples from infants in the delayed BCG group who had
610 received BCG before phlebotomy, who were Penta-vaccinated, or had hemolyzed samples were

611 excluded. Biosamples were shipped on dry ice to the *Precision Vaccines Program* (Boston, MA,
612 USA) for subsequent metabolomic assays (Figure S1). *In vitro* cytokine assays were conducted
613 as outlined below. For metabolomic and lipidomic assays, samples were selected per sex and
614 treatment based on the following criteria: 1) Exclusion criteria included a history of vomiting or
615 diarrhea per mother's report, hemolyzed samples, or limitation of available sample volume (i.e.,
616 <20 μ L); 2) Inclusion: To overcome the limitation of sample volumes, ten newborn samples
617 stratified by sex and treatment were pooled prior to shipment to *Metabolon* (Durham, North
618 Carolina, USA) for mass spectrometry-based metabolomics and lipidomic assays. These samples
619 were matched with their clinical information. To gain insight into the impact of BCG
620 immunization on both innate and adaptive immunity, blood was collected at four weeks and
621 stimulated *in vitro* with vehicle control (Roswell Park Memorial Institute medium, RPMI), *Toll*-
622 like receptor (TLR) agonists or PPD. After incubation, supernatants were collected and
623 cryopreserved prior to batch measurement of cytokines by multiplex assay. Clinical data with
624 corresponding *in vitro* stimulated blood derived from the early BCG (n=60) and control infants
625 (delayed BCG, n=60) included in this metabolomics study were reanalyzed and yielded
626 comparable baseline clinical characteristics (Table S1).

627
628 *Boston newborn cohort stimulated in vitro with BCG or saline control.* Coded human cord blood
629 samples (n=12) were collected from healthy term (≥ 37 weeks' gestation) elective cesarean
630 deliveries in accordance with approved protocols from the Institutional Review Boards of the
631 Beth Israel Deaconess Medical Center, Boston, MA, and The Brigham & Women's Hospital,
632 Boston, MA. Blood samples were anti-coagulated with 15 U/ml of clinical-grade pyrogen-free
633 heparin sodium and assayed within 4h. Blood collected was diluted 1:1 in RPMI medium and
634 stimulated in 96 well U-bottom plates with BCG-Tice (Merck, 1:1000 vol/vol) and saline vehicle
635 (1:1000 vol/vol). BCG-Tice was reconstituted with the provided diluent per manufacturer's
636 instructions and used within 4-6h after reconstitution. After 18 hr incubation at 37°C,
637 supernatants (90% plasma vol/vol) were collected and stored at -80°C. Two plasma aliquots were
638 submitted to *Metabolon, Inc* for metabolomics profiling and complex lipids platform. BCG-only
639 controls were included (High and Low concentration). For these samples, the 'High'
640 concentration corresponded to the reconstitution of the BCG vaccine in 1 ml saline, and the
641 'Low' concentration corresponded to a 1:1000 dilution. Three replicates of high concentration
642 and five replicates of low concentration were processed for each data stream.

643
644 *EPIC-001 cohort. Gambia in vivo newborn cohort EPI-vaccinated (BCG, HBV, OPV) at birth or*
645 *delayed-vaccinated* (Lee et al., 2019). As part of the EPIC-001 clinical study, pregnant mothers
646 were enrolled following informed consent. On the day of birth (DOL 0), peripheral blood
647 samples were obtained from all newborns pre-vaccination. These newborns, according to group
648 assignment, were then either immunized with EPI vaccines (oral polio vaccine (OPV), BCG and
649 Hepatitis B) at birth or after a delay. A follow-up blood sample collection was obtained from all
650 infants at either DOL 1, DOL 3, or DOL 7 with a maximum of two peripheral blood collections
651 per participant in the first week of life (Figure 1C, Figure S1C). Plasma preparation and
652 metabolomics assay for this cohort have been previously described (Lee et al., 2019).

653

654 **METHOD DETAILS**

655 **Global Untargeted Metabolomics Profiling**

656 Plasma metabolite profiling was conducted by Metabolon using in-house standards
657 (Evans et al., 2009; Long et al., 2017). Each plasma sample was stored at -80°C and accessioned
658 into the Metabolon Laboratory Information Management System (LIMS). To enable an
659 association with the original source identifier and for tracking purposes, each sample was
660 assigned a LIMS unique identifier. Samples were extracted and prepared for analysis using
661 Metabolon's solvent extraction method (Evans, 2008). Recovery standards were added to the first
662 step in the extraction process to ensure proper quality control. Protein was removed by methanol
663 precipitation under vigorous shaking for 2 mins (Glen Mills GenoGrinder 2000) then by
664 centrifugation. The supernatants were divided into five fractions: one for analysis by UPLC-
665 MS/MS with positive ion mode electrospray ionization, one for analysis by UPLC-MS/MS with
666 negative ion mode electrospray ionization, one for LC polar platform, one for analysis by GC-
667 MS, and one sample was reserved for backup. Samples were placed briefly on a TurboVap®
668 (Zymark) to remove the organic solvent. For LC, the samples were stored overnight under
669 nitrogen before preparation for analysis. For GC, each sample was dried under vacuum
670 overnight before preparation for analysis (Lawton et al., 2008).

671

672 **Complex Lipids Platform Lipidomics**

673 The Complex Lipid Panel (CLP) lipidomics data is a non-chromatographic, infusion-
674 based targeted discovery platform for a defined list of lipid species. This method does not
675 produce chromatographic peaks but analyzes a continual stream of lipid extract. No annotation/
676 identification of compounds is required because the methodology uses a combination of
677 empirically determined Ion Mobility properties and specifically designed multiple reaction
678 monitoring (MRM) transitions to uniquely target each lipid species during the analytical process.
679 Lipids were extracted from *in vivo* Guinea-Bissau newborn plasma samples and from cord blood
680 plasma after *in vitro* BCG stimulation in the presence of deuterated internal standards using an
681 automated butanol-method (BUME) extraction (Lofgren et al., 2012). Extracts were dried under
682 nitrogen and reconstituted in ammonium acetate dichloromethane: methanol then transferred to
683 vials for infusion-MS analysis employing a Shimadzu LC with nano PEEK tubing and the Sciex
684 SelexIon-5500 QTRAP. Samples were analyzed via both positive and negative mode
685 electrospray. The 5500 QTRAP was operated in multiple reaction monitoring modes (MRM)
686 with a total of >1,100 MRMs.

687

688 **TLR agonist- and PPD antigen- induced cytokine responses in blood derived from early vs. 689 delayed BCG immunized newborns**

690 To assess the effect of BCG administration to Guinea-Bissau study participants on
691 subsequent *in vitro* TLR agonist- (innate) and PPD antigen (adaptive)- induced cytokine
692 responses, heparinized blood collected at 4 weeks was diluted 1:9 with RPMI-1640 void of L-
693 Glutamine (Gibco, Life Technologies Europe BV) supplemented with Pyruvate 1 mM (Na-
694 pyruvate, Lonza; Copenhagen, Denmark) and L-Glutamine–Penicillin–Streptomycin 1X (Gibco,
695 Life Technologies). *In vitro* re-stimulation with phorbol 12-myristate 13-acetate (PMA) (100
696 ng/mL; Sigma-Aldrich) and ionomycin (1 µg/mL) (Sigma-Aldrich) as a positive control; PPD
697 antigen from *M. tuberculosis* (Statens Serum Institut, Copenhagen, Denmark) (10 µg/mL) to
698 assess the mycobacterial specific response; lipopolysaccharide (LPS) (10 ng/mL) (Sigma-
699 Aldrich) [a Toll-like receptor (TLR)4 agonist]; (S)-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-
700 palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH, trihydrochloride (Pam3CSK4) (1 µg/mL) [a TLR2/1
701 agonist] (InvivoGen); Thiazoloquinoline Compound (CL075) (1 µg/mL) [a TLR8/7 agonist]

702 (InvivoGen) employed 200 μ L round-bottom microtiter plates (NUNC; Roskilde, Denmark) in a
703 37°C humidified incubator with 5% CO₂ for 24 hr to assess the mycobacterial specific response
704 together with RPMI control. After 24h of culture, supernatants were collected and stored at \leq
705 -70° C until analysis. Cytokine concentrations were measured at SSI, employing an
706 immunobead-based multiplexed assay as previously described (Skogstrand et al., 2005).

707
708

709 **QUANTIFICATION AND STATISTICAL ANALYSIS**

710 **Global Metabolomics and Lipidomics Analysis**

711 For metabolomics, compounds were identified by comparison to Metabolon library
712 entries of standard metabolites (Evans et al., 2009). Biochemical identification was based on
713 three criteria: retention index (RI) within a narrow RI window of the proposed identification,
714 accurate mass match to the library ± 10 ppm, and the MS/MS forward and reverse scores
715 between the experimental data and authentic standards. The MS/MS scores were based on a
716 comparison of the ions present in the experimental spectrum to the ions present in the library
717 spectrum. Exact molecular mass data from redundant m/z peaks corresponding to the formation
718 of different parent and product ions were first used to help confirm the metabolite molecular
719 mass. Metabolon's *MassFragment*TM application manager (Waters MassLynx v4.1, Waters
720 Corp.; Milford, USA) facilitated the MS/MS fragment ion analysis process using peak-matching
721 algorithms and quantified using area-under-the-curve. All identified metabolites were
722 categorized as Level 1 metabolites according to reporting standards set by the Chemical Analysis
723 Working Group of the Metabolomics Standards Initiative (Members et al., 2007; Spicer et al.,
724 2017; Sumner et al., 2007), and appropriate orthogonal analytical techniques were applied to the
725 metabolite of interest and to a chemical reference standard. Level 1 identification included
726 analyses of two or more orthogonal properties of an authentic chemical standard. Metabolites
727 identified in our study had a corresponding accurate mass confirmed via MS with retention
728 index, chemical, and composition ID, and those with an exact matching mass were reported.

729
730 Raw data were measured based on LC-MS peak areas proportional to feature
731 concentration. Quality control measures were performed by the following steps: 1. Missingness
732 assessment of the data; 2. Missing values were imputed with half the minimum detected level for
733 a given metabolite; 3. Metabolites with an interquartile range of 0 and xenobiotics were excluded
734 from the analysis; 3. Features (relative peak intensities) were log-transformed, normalized then
735 pareto-scaled to reduce variations. 4. Visual inspection with Principal Component Analysis
736 (Figure S2A-J). Statistical analyses for univariate, chemometrics, and clustering analysis used in-
737 house algorithms, R statistical packages, and *MetaboAnalyst 4.0* (Xia et al., 2015; Xia and
738 Wishart, 2016). Metabolite super pathways consist of biochemical metabolite annotation
739 corresponding to their general metabolic class, including amino acid, carbohydrate, lipid,
740 nucleotide, energy, peptide, cofactors and vitamins, and xenobiotics. We filtered out the
741 xenobiotics to only focus on endogenous metabolites. Each super pathway is further subdivided
742 into ≥ 2 more specific sub-pathways. The hypergeometric test in *MetaboAnalyst* was specified for
743 the over-representation analysis and relative-betweenness centrality for the pathway topology
744 analysis.

745
746 Pathway analyses and visualization employed *MetaboAnalyst 4.0* Metabolite Set
747 Enrichment Analysis (MSEA) based on the KEGG Pathway (www.genome.jp/kegg/) and the

748 Human Metabolome Database Version 3.6 (HMDB). MSEA identifies biologically meaningful
749 patterns in changes in metabolite concentrations by evaluating the significance individually
750 under each condition. Metabolites that reached significance ($\alpha=0.05$) were combined in an
751 effort to detect meaningful patterns and investigate if a group of functionally related metabolites
752 was enriched. This method can identify subtle but consistent changes among metabolites that
753 may not be detected by conventional approaches (Jia et al., 2014; Xia and Wishart, 2011, 2016).
754 To enhance the robustness of our findings despite small effect sizes, we have focused on
755 pathways that are perturbed after comparison to their own controls across multiple cohorts *in*
756 *vivo* and *in vitro*. Statistical modeling was based on data distribution for each dataset. For plasma
757 metabolomic data from Guinea-Bissau *in vivo* samples, early and delayed BCG groups were
758 compared using unpaired t-test with Welch's correction. For the Gambia cohort, the peripheral
759 blood was profiled twice over the first week of life at DOL0 and at a second point at either
760 DOL1, 3, or 7. Univariate analyses were performed by analyzing paired differences per
761 participant, referred to as indexing. The analysis then proceeds by looking for differences
762 between treatments (delayed vs. EPI-vaccinated) rather than DOL.

764 For lipidomics, individual lipid species were quantified by comparing the ratio of the
765 signal intensity of each target compound to that of its assigned internal standard, then
766 multiplying by the concentration of internal standard added to the sample. Lipid class
767 concentrations were calculated from the sum of all molecular species within a class, and fatty
768 acid compositions were determined by calculating the proportion of each class comprised of
769 individual fatty acids. Of note, some of the same lipids detected in both platforms are named
770 differently due to conventions employed when the libraries for each platform were initially
771 developed (e.g., 1-palmitoyl-GPC (16:0) in Global and LPC (16:0) in CLP). Additionally, some
772 isomers can be resolved on the Global platform (e.g., 1-oleoyl-GPC (18:1) and 2-oleoyl-GPC
773 (18:1)) while CLP reports the total of both (LPC 18:1). Missing values were imputed by
774 assigning them the minimum observed value for each compound. A similar approach used for *in*
775 *vivo* and *in vitro* metabolomics, namely log-transformation and modeling, was applied to identify
776 lipids that differed significantly between experimental groups. The *Surveyor* program was
777 employed for data organization and visualization of the fatty acids measured. Statistical analyses
778 for metabolomics and lipidomics employed R version 3.4.1. Comparisons with $p<0.05$ were
779 considered statistically significant with figure asterisks denoting level of significance (* $p<0.05$;
780 ** $p<0.01$; *** $p<0.001$). Lipid species coverage and concentrations for *in vivo* and *in vitro*
781 studies are further described in Tables S9 and S10.

783 Targeted Assays

784 Plasma cytokine and chemokine concentrations were measured by multiplex assay, using
785 a Flexmap 3D system with Luminex xPONENT software version 4.2 (Luminex Corp.; Austin,
786 TX, USA). Cytokines and chemokines were measured using Milliplex Analyst software (v.
787 3.5.5.0, Millipore). Infant blood from the Guinea Bissau infant cohort was diluted and stimulated
788 *in vitro* with PPD or TLR agonists and cytokine and chemokine production measured as
789 previously described (Jensen et al., 2015). Cytokine and chemokine production from blood
790 derived from the subset of newborn participants included in our metabolomics and lipidomics
791 study was analyzed using an unpaired Wilcoxon Rank-sum Test. Comparisons with $p<0.05$ were
792 considered statistically significant with figure asterisks denoting level of significance (* $p<0.05$;
793 ** $p<0.01$; *** $p<0.001$). Data are depicted as medians.

794 For the Boston cohort, a heatmap was generated, and treatment groups were compared
795 using two-sample t-tests with Benjamini, Krieger, and Yekutieli correction by comparing BCG-
796 stimulated vs. vehicle control conditions from the same participants. Individual metabolites were
797 compared using a repeated-measures approach (Wilcoxon matched-pairs rank-sum test).
798 Comparisons with $p < 0.05$ were considered statistically significant with figure asterisks denoting
799 level of significance (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$). Data are shown as means \pm SEM.

800

801 **Data Deposition**

802 Data files for metabolomics and lipidomics were deposited in ImmPort under accession numbers:
803 SDY1376 and SDY1709.

804

805 **Supplemental Information**

806 Supplemental information includes five figures and ten tables.

807

808 **Author Contributions**

809 Conceptualization: JDA, CB, OL; Clinical: JDA, KJ, BK, CB; Methodology: JDA, SvH, MP;
810 Formal Analysis, JDA, RK, JLS, AO; Writing-Original Draft: JDA, KJ, AA, GC; Writing-
811 Review & Editing: AA, RK, SvH, HS, JLS, AO, BK, TK, CB, OL; Resources: OL; Supervision:
812 OL; Funding Acquisition: OL.

813

814 **Acknowledgments**

815 We thank the participant families, nurses, and physicians of the Bandim Health Project
816 for enabling sample collection. We appreciate the Medical Research Council Gambia team for
817 recruitment, enrollment, and acquisition of samples. We also thank the Departments of Newborn
818 Medicine at the Brigham and Women's Hospital and Beth Israel Deaconess Medical Center for
819 cord blood collection. We thank Dr. Karen Pepper of MIT for providing valuable feedback and
820 editing the manuscript, Kristin Johnson of Boston Children's Hospital for illustrations, Sofia
821 Vignolo, Tanzia Shaheen, Annmarie Hoch for data deposition, and Diana Vo for programmatic
822 support. The European Research Council supported the randomized trial of BCG to CB (starting
823 grant ERC-2009-StG-243149), the Danish National Research Foundation (grant DNRF108 to
824 Research Center for Vitamins & Vaccines), and DANIDA, European Union FP7, and
825 OPTIMUNISE (grant Health-F3-2011-261375 to the Bandim Health Project); the
826 immunological sub-group study of early BCG vaccination was supported by Novo Nordisk
827 Foundation and a Ph.D. scholarship grant from University of Southern Denmark to KJ; KJ is
828 supported by a grant from Novo Nordisk Foundation (grant NNF14OC0012169).

829 This study was supported by the National Institute of Health/National Institute of Allergy &
830 Infectious Diseases Human Immunology Project Consortium Grant U19AI118608 and
831 Molecular Mechanisms of Combinations Adjuvants Grant U01 AI124284, as well as the BCH
832 *Precision Vaccines Program*. AA and OL were supported in part via the Mueller Health
833 Foundation.

834

835 **Declaration of Interests**

836 O.L is a named inventor on several Boston Children's Hospital patents relating to human
837 microphysiologic assay systems and vaccine adjuvants. S.M and G.M are employees of
838 Metabolon Inc. The other authors declare no competing financial interests.

839

840 **Figure Titles and Legends**

841 **Graphical abstract:**

842 **BCG vaccination perturbs metabolic pathways *in vivo* and *in vitro*.**

843 Vaccines have traditionally been developed empirically, with limited insight into their
844 impact on molecular pathways. Metabolomics provides a new approach to characterizing vaccine
845 mechanisms but has not yet been applied to human newborns, who are at the highest risk of
846 infection and receive the most vaccines. Bacille Calmette-Guérin (BCG) prevents disseminated
847 mycobacterial disease in children and can induce broad protection to reduce mortality due to
848 non-TB infections. Underlying mechanisms are incompletely characterized. Employing mass
849 spectrometry-based metabolomics, we demonstrate that early BCG administration alters the
850 human neonatal plasma metabolome, especially lipid metabolic pathways such as
851 lysophosphatidylcholines (LPCs), both *in vivo* and *in vitro*. Plasma LPCs correlated with both
852 innate TLR-mediated and PPD antigen-induced cytokine responses suggesting that BCG-induced
853 lipids might contribute to the immunogenicity of this vaccine. Vaccine-induced metabolic
854 changes may provide fresh insights into vaccine immunogenicity and inform the discovery and
855 development of early life vaccines.

856
857 **Figure 1: Schematic of *in vivo* (A), *in vitro* (B), and validation cohort (C) for BCG**
858 **vaccination experimental setup.**

859 (A) Study design and participant plasma biosample flow chart. Low birth weight newborns in
860 Guinea-Bissau were assigned to delayed BCG (catch-up BCG after blood collection) or
861 early BCG (vaccinated with BCG at birth). In an immunological study nested within the
862 trial, capillary blood samples were collected four weeks after randomization to
863 investigate the effect of BCG on TLR agonist-induced and PPD antigen recall cytokine
864 responses. After the primary analyses (Jensen et al., 2015), plasma biosamples of
865 sufficient volume were utilized for subsequent metabolomic and lipidomic assays. To
866 ensure sufficient sample volume for robust metabolite detection, metabolomics (Q
867 Exactive, Thermo Scientific, Metabolon Inc; Durham, NC) and complex lipid panel
868 lipidomics (CLP, Metabolon Inc) were conducted on pooled plasma from N = 10
869 newborns of the same sex and vaccine treatment.

870 (B) To further assess BCG's impact on the plasma metabolome, we modeled BCG vaccine
871 responses *in vitro* in cord blood from a cohort of newborns in Boston, USA. Similarly,
872 supernatants from these *in vitro* stimulated samples were subjected to high throughput
873 metabolomic, lipidomic, and cytokine/chemokine assays, and results indexed to the same
874 participant's vehicle (saline) control.

875 (C) For validation purposes, we compared the metabolomics profile of Guinea-Bissau *in vivo*
876 and Boston *in vitro* cohorts with another independent newborn group from The Gambia
877 (West Africa)(Lee et al., 2019). Newborns were assigned to either receive the Expanded
878 Program on Immunization (EPI) vaccines (OPV, BCG, and HBV) at birth or delayed
879 during the first week of life to study the effect of vaccine responses on early life immune
880 ontogeny. Paired samples were analyzed by indexing their DOL0 (day of birth) samples
881 and a follow-up timepoint at DOL1, DOL3, or DOL7. Regardless of their timepoint
882 assignment, the newborns were combined into their assigned treatment groups (EPI-
883 vaccinated vs. delayed-vaccinated) for the purposes of analysis.

884
885 **Figure 2: BCG immunization perturbed the human neonatal plasma metabolome.**

- 886 (A) Schematic layout of blood collection for the *in vivo* Guinea-Bissau newborn cohort. Early
887 BCG denotes newborn participants given BCG together with OPV at birth. Delayed BCG
888 represents newborn participants who received only OPV at birth and BCG catchup after
889 the 4-week blood collection.
- 890 (B) Multivariate sparse Partial Least Square Discriminant Analysis (sPLS-DA) applied to
891 metabolic data demonstrated differences between delayed BCG and early BCG
892 newborns.
- 893 (C) Top 30 loading plot of each feature selected on the first component in between treatments
894 with a maximal median value for each metabolite. Blue bars denote metabolites
895 associated with delayed BCG, while orange bars denote metabolites associated with early
896 BCG.
- 897 (D) Unsupervised hierarchical clustering of differentially abundant metabolites (DAMs)
898 revealed significant differences in lipid and amino acid responses between early and
899 delayed BCG.
- 900 (E) A plot of the ratio of metabolites in the BCG vs. delayed groups depicts all identified
901 metabolites by category comparing early vs. delayed BCG. Significant metabolites were
902 identified per metabolite class, annotated with red for significant metabolites ($p < 0.05$),
903 pink for nearly significant metabolites ($0.05 < p < 0.1$), and gray for non-significant
904 metabolites. Of the seven metabolite categories that differed between the early and
905 delayed BCG groups, lipid metabolites were particularly and significantly perturbed by
906 BCG. Data are presented as \log_2 fold-change of early vs. delayed BCG.

907
908 **Figure 3: Early administration of BCG to human newborns *in vivo* altered the plasma**
909 **lipidome.**

910 Network reconstruction of BCG-altered metabolic pathways demonstrated perturbation of lipid
911 metabolism.

- 912 (A) Over half of identified metabolites induced by newborn BCG vaccination belonged to the
913 lipid class, followed by amino acids. Among the significantly altered lipids, 70% (24
914 identified metabolites) of the lipids belonged to the lysophospholipid (LPL) subclass.
915 Data are presented as counts of significant lipids.
- 916 (B) Examples of significantly different lipid metabolites between the early vs. delayed BCG
917 groups. Boxplots display medians with lower and upper hinges representing first and
918 third quartiles; whiskers reach the highest and lowest values no more than 1.5x
919 interquartile range from the hinge. Welch's t-test was used for data analysis. Data
920 presented are the scaled, normalized peak intensities of the metabolites. * $P < 0.05$;
921 ** $P < 0.01$; *** $P < 0.001$ vs. control.
- 922 (C) Pathway-based network reconstruction of DAMs from 4-week-old infants vaccinated
923 with BCG in the first week of life compared to the delayed BCG group (*Metscape* on
924 *Cytoscape* 3.4.0). The illustrated lipid pathways include lipid biosynthesis pathways
925 (steroid hormone, fatty acid, androgen and estrogen, cholesterol), glycerophospholipid,
926 glycosphingolipid, omega 6-fatty acid, prostaglandin, and arachidonic acid metabolism.
927 Legend key represents detected metabolites, levels comparing early vs. delayed BCG:
928 down (blue), up (red), white (unchanged), and gray (undetected) with their \log_2 fold-
929 change values.

930
931 **Figure 4: Plasma lipidomics reveals biomarkers of neonatal BCG vaccination.**

- 932 (A) Complex lipid panel pipeline schematic diagram. Lipid extracts were subjected to LC-
933 MS/MS analyzed via both positive and negative mode electrospray. Lipids were profiled
934 and identified based on known lipid reference standards. The statistical analyses
935 employed are described in the Methods section.
- 936 (B) Lipidomics panel identified 963 lipids from the *in vivo* newborn cohort belonging to 14
937 different lipid subclasses, with triglycerides being the most abundant. Data represent
938 counts of identified lipids.
- 939 (C) Supervised sPLS-DA from Guinea-Bissau newborns distinctly discriminated lipids
940 between early and delayed BCG groups with PC1 accounting for 52% of variance and
941 PC2 for 15% variance.
- 942 (D) Early administration of BCG at birth significantly perturbs plasma lipid concentrations at
943 4 weeks of age. Significantly altered lipid metabolites in the early vs. delayed BCG
944 newborn group were annotated in red ($P < 0.05$), those that were nearly significant in
945 pink ($P < 0.1$ to $P > 0.05$), and those that were not significant in gray.
- 946 (E) Stimulation of human newborn cord blood *in vitro* with BCG perturbs phospholipid
947 pathways. Supernatants from blood stimulated *in vitro* for 18 hr with vehicle control, or
948 BCG were subjected to lipidomics and demonstrated much lower production of lipids
949 compared to control. Significantly altered lipid metabolites in the BCG vs. vehicle
950 conditions were annotated in red ($P < 0.05$), those that were nearly significant in pink (P
951 < 0.1 to $P > 0.05$), and those that were not significant in gray.
- 952 (F) The majority of significantly perturbed lipids were decreased both *in vitro* following 18
953 hr BCG stimulation and *in vivo* following early BCG immunization, reflecting a BCG-
954 induced metabolic signature. Comparison of significant lipids between the *in vivo*
955 Guinea-Bissau and *in vitro* Boston cohorts reported as \log_2 fold-change of early
956 BCG/delayed BCG (Guinea-Bissau) and BCG-stimulated/control (Boston). With the
957 exception of free fatty acid components and LPC 16:0, the directionality of lipid fold-
958 changes was similar *in vivo* and *in vitro*.
- 959 (G) Concentrations of multiple LPC components were significantly decreased in BCG-
960 stimulated samples *in vivo* and *in vitro*. Data are presented as \log_2 FC of early vs. delayed
961 (or no) BCG.

962
963 **Figure 5. Addition of BCG to human newborn cord blood *in vitro* induced changes in**
964 **plasma sugar, amino acid, and lipid pathways.**

- 965 (A) Human newborn cord blood was stimulated *in vitro* with vehicle control (saline) or BCG
966 for 18 hr, and the extracellular fluid (90% plasma vol/vol) was collected by centrifugation
967 for metabolomics analysis as described in Methods. The principal component analysis
968 demonstrated a marked separation of metabolites between BCG-stimulated and vehicle-
969 stimulated newborn samples as indicated by the ellipses.
- 970 (B) Unsupervised hierarchical clustering revealed major differences between treatments.
971 BCG stimulation of blood was associated with a reduction in many metabolites,
972 especially in the lipid pathway. Each column represents individual samples; BCG-stim
973 denotes BCG-stimulated blood; Control denotes vehicle control.
- 974 (C) Top 50 enrichment overview based on metabolite set enrichment analysis (MSEA;
975 *MetaboAnalyst*) highlighted pathways that were prominently altered after BCG
976 stimulation, including those relating to the glucose-alanine cycle, lactose, and
977 sphingolipid metabolism. Fold enrichment was calculated by dividing the observed

978 number of hits by the expected number of hits of the overrepresented pathway. MSEA
979 calculates a hypergeometric test score employing a cumulative binomial distribution
980 based on the probability of seeing at least a particular number of metabolites with the
981 biological term of interest in a given compound list.
982 (D) The volcano plot illustrated BCG-induced changes in metabolites as compared to vehicle
983 control. Red color represents significant ($P < 0.05$), pink marginally significant ($P < 0.1$
984 to $P > 0.05$), and gray non-significant lipids.

985
986 **Figure 6: BCG-induced plasma lysophospholipids correlated with TLR- and mycobacterial**
987 **antigen-induced cytokine responses.**

988 Peripheral blood was collected from early vs. delayed BCG immunized infants in Guinea Bissau
989 at 4 weeks of age and diluted for *in vitro* TLR agonist- and PPD-induced stimulation assay as
990 previously described (Jensen et al., 2015).

991 (A-F) Early administration of BCG was associated with perturbation of multiple LPCs as
992 compared to delayed BCG. LPC concentrations are depicted as boxplots. Significance
993 was calculated using the Mann-Whitney Rank Test between unpaired samples.

994 (G) Cytokines and chemokines were measured after multiple antigen recall responses of
995 delayed and early BCG newborn samples. Response from PMA, LPS (TLR4 agonist),
996 PAM3CSK4 (TLR 2/1 agonist), CLO75 (TLR 7/8), and PPD were correlated for
997 corresponding matched samples using Pearson correlations of all LPCs. Data are
998 presented as correlation estimates of cytokines/chemokines vs. LPCs. These estimates
999 were calculated from \log_2 fold-changes for early BCG vs. delayed BCG.

1000 (H) The summary correlation coefficient (R) from selected significant cytokine and LPC
1001 correlations is depicted on a forest plot. The plot presented significant correlations with
1002 corresponding 95% CIs.

1003 **Figure 7: Concordance of significant metabolites across distinct human newborn cohorts**
1004 **demonstrates a common BCG-induced metabolic trajectory in early life.**

1005 (A) Untargeted global metabolomics profiling was conducted on peripheral blood of
1006 newborns vaccinated with EPI vaccines (BCG, HBV, and OPV) in The Gambia (n= 27)
1007 during the first week of life. Venn diagram summarizes the number of shared metabolite
1008 sets enriched after metabolite set enrichment analysis (MSEA, *MetaboAnalyst*) in The
1009 Gambia *in vivo* cohort (green), Boston *in vitro* cohort (yellow), and Guinea-Bissau *in*
1010 *vivo* 4-week blood collection (blue).

1011 (B) A number of significant metabolites per cohort based on their pattern level are illustrated.
1012 Data are presented as counts of significantly decreased or increased metabolites. BCG-
1013 induced fold-changes were calculated as compared to control groups.

1014 (C) Significant metabolites shared by two or more cohorts were depicted as a heatmap with
1015 their log fold-change values comparing BCG-vaccinated vs. delayed (GB)/non-BCG
1016 vaccinated (Gambia) or BCG-stimulated vs. control for the Boston *in vitro* cohort. Paired
1017 samples were analyzed for Gambia and Boston samples, respectively. Direction of
1018 change is indicated by color code: blue, down; red, up; grey, not quantified.

1019 (D) Chord diagram of vaccine-induced metabolite associations revealed shared metabolite
1020 sets with vaccination compared to each control (Guinea-Bissau: blue, Boston: yellow,
1021 Gambia: green). Metabolite set bar widths are proportional to the number of associations
1022 across groups. Individual chords connected to each metabolite set indicate associations
1023 resulting from MSEA analysis.

1024 **Supplementary Figures:**

1025 **Figure S1. Flow chart of individuals with plasma samples analyzed in the study.**

- 1026 (A) Low birth weight newborns in Guinea Bissau were randomized to receive BCG at birth
1027 (early BCG) or delayed by 6 weeks (delayed BCG). In an immunological study nested
1028 within the trial, capillary blood samples were collected four weeks after randomization to
1029 assess the effect of BCG on *in vitro* antigen-induced recall cytokine responses. After the
1030 primary analyses (Jensen et al., 2015), remaining plasma samples of sufficient volume
1031 were utilized for subsequent metabolomic and lipidomic assays.
- 1032 (B) Human newborn cord blood samples (n= 12) were collected from healthy term newborns
1033 (≥ 37 weeks gestation) for *in vitro* stimulation with vehicle (saline) or BCG. The plasma
1034 samples were processed for metabolomics, complex lipid panel lipidomics, and multiplex
1035 cytokine/chemokine assays.
- 1036 (C) Newborns were recruited in The Gambia (West Africa). Each newborn provided a
1037 peripheral blood sample at the day of birth (DOL0) and subsets of newborns, each
1038 providing a second peripheral blood sample at either DOL1, 3, or 7. The newborns were
1039 assigned to either delayed-vaccinated up to 1 week (participant n= 13, total samples
1040 n=26) or EPI-vaccinated at birth (participant n=14, total samples n=28). Newborn
1041 peripheral venous blood was drawn directly into heparinized collection tubes and
1042 subjected to metabolomic assay.

1043
1044 **Figure S2: Summary of quality control and assurance method for metabolomics Guinea-**
1045 **Bissau (in vivo, upper panel) and Boston (in vitro, lower panel) datasets.**

- 1046 (A) and (F) Histogram of percent missing values for each metabolite
1047 (B) and (G) Histogram of percent missing values for each sample
1048 (C) and (H) Quality control and assurance metrics summary table
1049 (D) and (I) Pre-processing distribution before scaling and normalization
1050 (E) and (J) Post-processing distribution after scaling and normalization

1051
1052 **Figure S3: Addition of BCG to human newborn cord blood *in vitro* perturbs the eicosanoid**
1053 **lipid pathway.**

- 1054 (A) Heparinized human cord blood was stimulated with saline control or BCG vaccine for 18
1055 hr after which the extracellular medium was collected and analyzed via complex lipid
1056 panel lipidomics. BCG alone was tested at high (1:10 v/v) and low (1:1000v/v)
1057 concentrations as controls. For *in vitro* studies, the 1:1000 vol/vol ratio was used. A
1058 summary of the number of lipids quantified is illustrated. Data are presented as mean \pm
1059 SEM.
- 1060 (B) Comparison of lipid families showed that BCG-only controls (BCG vaccine alone) have
1061 lower measured lipids in most families than cord blood stimulated with vehicle or BCG.
1062 For *in vitro* treatments, BCG low (1:1000 vol/vol) concentration was used to stimulate
1063 cord blood. Lipid families with very low or undetectable concentrations after BCG-only
1064 low or BCG cord stimulation (1:1000 vol/vol) are depicted in red.
- 1065 (C) The Venn diagram of detected lipids illustrates that BCG-only controls had fewer lipids
1066 detected than *in vitro* control- or BCG-stimulated cord blood samples.
- 1067 (D-F) BCG-induced differentially abundant lipids (DALs) included fatty acid components
1068 such as prostaglandin E₂ (PGE₂) (panel D), docosahexaenoic acid (DHA 22:6) (panel E),
1069 linoleic acid (FFA 18:2) (panel G), and arachidonic acid (FFA 20:4) (panel H) suggesting

1070 BCG modulates lipid mediators of inflammation (panel F). BCG induced a pro-inflammatory
1071 eicosanoid pathway pattern *in vitro*, decreasing anti-inflammatory DHA 22:6, FFA 18:2, and
1072 FFA 20:4 while increasing pro-inflammatory PGE₂. Statistical analyses employed repeated
1073 measures t-test for participant samples. Data are presented with box and whiskers depicting
1074 quartiles and variability outside the quartiles.
1075

1076 **Figure S4: Early BCG group demonstrated enhanced cytokine production upon PPD re-**
1077 **stimulation of heparinized blood collected 4 weeks post BCG vaccination.**

1078 (A-G) PPD-induced cytokines were compared in the early vs. delayed BCG groups. The
1079 early BCG group demonstrated significantly greater PPD-induced production of TNF α , IL5,
1080 IL6, IL17 and IFN γ . Groups were compared using the Wilcoxon Rank Sum Test. Data are
1081 depicted as geometric means. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$
1082

1083 **Figure S5: BCG-induced cytokine and chemokine production in Boston human newborn**
1084 **cord blood *in vitro*.**

1085 (A) Heatmap depicting changes in the production of 41 selected cytokines and chemokines
1086 after BCG *in vitro* stimulation for 18 hr. Two-sample t-tests with Benjamini, Krieger and
1087 Yekutieli correction comparing BCG-stimulated vs. vehicle control * $P < 0.05$; ** $P <$
1088 0.01 ; *** $P < 0.001$. Data are reported using Euclidean distance and Ward algorithm.
1089 (B-E) Selected inflammatory cytokines showed differences between vehicle control
1090 stimulated cord blood vs. BCG-stimulated cord blood. Paired student t-test used for data
1091 analysis * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$
1092
1093
1094
1095

1096

1097 **Table S1: Characteristics of newborn groups for Guinea-Bissau *in vivo* metabolomics**
1098 **profiling**

1099 Clinical data analyses for the study participants were assessed by metabolomics. Missing values
1100 were excluded. After the blood draw at 4 weeks after birth, the delayed group received catch-up
1101 BCG vaccination within 2 months of life. Normally distributed numerical values were tested
1102 with unpaired *t*-test with Welch's correction, presented as means with 95% confidence intervals
1103 (CI).

1104 *Significantly different ($p < 0.05$).

1105 Abbreviations: BCG, Bacillus Calmette–Guérin; PPD, purified protein derivative; TST, Mantoux
1106 tuberculin skin test.

1107

1108 **Table S2: Significantly altered plasma metabolites in the early vs. delayed BCG group.** An
1109 unpaired *t*-test with Welch's correction was employed (nom. $p < 0.05$) to identify altered
1110 metabolites in plasma samples derived from newborns receiving early vs. delayed BCG. Please
1111 see the spreadsheet.

1112

1113 **Table S3: BCG-Induced Metabolite Pathways enriched in newborn cohorts.** Metabolite Set
1114 Enrichment Analysis (MSEA) employed *MetaboAnalyst* to evaluate and group significant
1115 metabolites for each cohort, including Guinea-Bissau and Gambia *in vivo* and Boston *in vitro*.
1116 The table includes identified metabolite sets, the total number of metabolites corresponding to
1117 each set, expected metabolites, and the number of hits per cohort.

1118

1119 **Table S4: A birth dose of BCG induced plasma lipidome changes *in vivo*.**

1120 Plasma from newborns in Guinea-Bissau whose blood was collected after 4 weeks for early vs.
1121 delayed BCG vaccination was subjected to lipidomics. Differentially abundant lipids (DALs)
1122 between treatment groups are reported along with their corresponding pathway, super-pathway,
1123 sub-pathway, lipid identification platforms, fold-change upon early BCG immunization (i.e.,
1124 early BCG vs. delayed BCG), and significance.

1125

1126 **Table S5: BCG induced changes in plasma metabolites in newborn cord blood *in vitro*.**

1127 Human newborn cord blood was stimulated *in vitro* for 18 hr with BCG (1:1000 vol:vol) or
1128 saline control prior to collecting the extracellular medium for metabolomics. Matrices were
1129 computed for indexed matched samples comparing BCG stimulation vs. saline vehicle control
1130 using the *WithinVariation* function in R package *mixOmics* v. 6.1.2. (See spreadsheet in the
1131 supplementary materials).

1132

1133 **Table S6: Tobit regression analysis of cytokine responses of *ex vivo* stimulated (PPD and**
1134 **control) whole blood samples from the Guinea-Bissau newborn cohort (pg/mL).**

1135 Cytokine measurements were performed on early BCG and delayed BCG newborn samples
1136 stimulated *in vitro* with RPMI control and PPD at 4 weeks as described (Jensen et al., 2015;
1137 Skogstrand et al., 2005). Results are reported as geometric mean ratios (GMR) and 95%
1138 confidence intervals (CI) with concentrations in pg/mL; $n = 119$. Cytokines whose concentrations
1139 significantly differed between the early vs. delayed BCG group are indicated in bold.

1140 Abbreviations: BCG, Bacillus Calmette–Guérin; CI, confidence interval; PPD, purified protein
1141 derivative TB test; GMR, geometric mean range

1142 **Table S7: Addition of BCG to human cord blood *in vitro* induced plasma lipidome changes.**

1143 Human cord blood collected from a Boston cohort was stimulated *in vitro* for 18 hours with
1144 vehicle control vs. BCG. The extracellular medium (90% plasma vol/vol) was subsequently
1145 analyzed by lipidomics. Identified lipids were analyzed using a repeated-measures test for
1146 matched participants. Significant lipids were reported with their corresponding pathway, super-
1147 pathway, sub-pathway, platforms used, fold-change of treatment (matched BCG-stimulated vs.
1148 control), and significance level.

1149
1150 **Table S8 EPI-vaccination at birth alters the plasma metabolome.** Significant plasma
1151 metabolites in the EPI-vaccinated vs. delayed vaccinated (in the first week of life) newborns are
1152 shown. Peripheral blood was collected from a human newborn cohort in The Gambia (West
1153 Africa) that received EPI immunization (BCG, HBV, and OPV) either at birth (Day of Life
1154 (DOL)-0) or delayed immunization to DOL-7. Blood was promptly fractionated to generate
1155 cryopreserved plasma that was batch-analyzed for global metabolomics. Data were analyzed
1156 taking into account treatment groups (EPI-vaccinated at birth vs. delayed) and DOL.

1157
1158 **Table S9: Complex Lipid Panel lipidomics Guinea Bissau *in vivo*,** Assay coverage, individual
1159 lipid class species, and concentrations (μM) are reported.

1160
1161 **Table S10: Complex Lipid Panel lipidomics Boston *in vitro*.** Assay coverage, individual lipid
1162 class species, and concentrations (μM) are reported.

1163
1164

1165 **References**

- 1166 Ackerman, M.E., Barouch, D.H., and Alter, G. (2017). Systems serology for evaluation of HIV
1167 vaccine trials. *Immunol Rev* 275, 262-270.
- 1168 Almeida, P.E., Silva, A.R., Maya-Monteiro, C.M., Töröcsik, D., D'Ávila, H., Dezsö, B.,
1169 Magalhães, K.G., Castro-Faria-Neto, H.C., Nagy, L., and Bozza, P.T. (2009). Mycobacterium
1170 bovis Bacillus Calmette-Guérin Infection Induces TLR2-Dependent Peroxisome Proliferator-
1171 Activated Receptor γ Expression and Activation: Functions in Inflammation, Lipid Metabolism,
1172 and Pathogenesis. *The Journal of Immunology* 183, 1337-1345.
- 1173 Amenyogbe, N., Levy, O., and Kollmann, T.R. (2015). Systems vaccinology: a promise for the
1174 young and the poor. *Philos Trans R Soc Lond B Biol Sci* 370.
- 1175 Andersen, A., Fisker, A.B., Rodrigues, A., Martins, C., Ravn, H., Lund, N., Biering-Sorensen,
1176 S., Benn, C.S., and Aaby, P. (2018). National Immunization Campaigns with Oral Polio Vaccine
1177 Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials. *Front*
1178 *Public Health* 6, 13.
- 1179 Angelidou, A., Conti, M.G., Diray-Arce, J., Benn, C.S., Shann, F., Netea, M.G., Liu, M., Potluri,
1180 L.P., Sanchez-Schmitz, G., Husson, R., *et al.* (2020a). Licensed Bacille Calmette-Guerin (BCG)
1181 formulations differ markedly in bacterial viability, RNA content and innate immune activation.
1182 *Vaccine* 38, 2229-2240.
- 1183 Angelidou, A., Diray-Arce, J., Conti, M.G., Netea, M.G., Blok, B.A., Liu, M., Sanchez-Schmitz,
1184 G., Ozonoff, A., van Haren, S.D., and Levy, O. (2021). Human Newborn Monocytes
1185 Demonstrate Distinct BCG-Induced Primary and Trained Innate Cytokine Production and
1186 Metabolic Activation In Vitro. *Front Immunol* 12, 674334.
- 1187 Angelidou, A., Diray-Arce, J., Conti, M.G., Smolen, K.K., van Haren, S.D., Dowling, D.J.,
1188 Husson, R.N., and Levy, O. (2020b). BCG as a Case Study for Precision Vaccine Development:
1189 Lessons From Vaccine Heterogeneity, Trained Immunity, and Immune Ontogeny. *Front*
1190 *Microbiol* 11, 332.
- 1191 Arts, R.J.W., Moorlag, S., Novakovic, B., Li, Y., Wang, S.Y., Oosting, M., Kumar, V., Xavier,
1192 R.J., Wijmenga, C., Joosten, L.A.B., *et al.* (2018). BCG Vaccination Protects against
1193 Experimental Viral Infection in Humans through the Induction of Cytokines Associated with
1194 Trained Immunity. *Cell Host Microbe* 23, 89-100 e105.
- 1195 Behar, S.M., Divangahi, M., and Remold, H.G. (2010). Evasion of innate immunity by
1196 Mycobacterium tuberculosis: is death an exit strategy? *Nature Reviews Microbiology* 8, 668-
1197 674.
- 1198 Biering-Sorensen, S., Aaby, P., Lund, N., Monteiro, I., Jensen, K.J., Eriksen, H.B., Scholtz-
1199 Buchholzer, F., Jorgensen, A.S.P., Rodrigues, A., Fisker, A.B., *et al.* (2017). Early BCG-
1200 Denmark and Neonatal Mortality Among Infants Weighing <2500 g: A Randomized Controlled
1201 Trial. *Clin Infect Dis* 65, 1183-1190.
- 1202 Blok, B.A., de Bree, L.C.J., Diavatopoulos, D.A., Langereis, J.D., Joosten, L.A.B., Aaby, P., van
1203 Crevel, R., Benn, C.S., and Netea, M.G. (2020). Interacting, Nonspecific, Immunological Effects
1204 of Bacille Calmette-Guerin and Tetanus-diphtheria-pertussis Inactivated Polio Vaccinations: An
1205 Explorative, Randomized Trial. *Clin Infect Dis* 70, 455-463.
- 1206 Boothby, M., and Rickert, R.C. (2017). Metabolic Regulation of the Immune Humoral Response.
1207 *Immunity* 46, 743-755.
- 1208 Brook, B., Harbeson, D.J., Shannon, C.P., Cai, B., He, D., Ben-Othman, R., Francis, F., Huang,
1209 J., Varankovich, N., Liu, A., *et al.* (2020). BCG vaccination-induced emergency granulopoiesis
1210 provides rapid protection from neonatal sepsis. *Sci Transl Med* 12.

- 1211 Carneiro, A.B., Iaciura, B.M., Nohara, L.L., Lopes, C.D., Veas, E.M., Mariano, V.S., Bozza,
1212 P.T., Lopes, U.G., Atella, G.C., Almeida, I.C., *et al.* (2013). Lysophosphatidylcholine triggers
1213 TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in
1214 peritoneal macrophages by inhibiting NF-kappaB translocation and MAPK/ERK
1215 phosphorylation. *PLoS One* 8, e76233.
- 1216 Chen, M., Divangahi, M., Gan, H., Shin, D.S.J., Hong, S., Lee, D.M., Serhan, C.N., Behar, S.M.,
1217 and Remold, H.G. (2008). Lipid mediators in innate immunity against tuberculosis: opposing
1218 roles of PGE2 and LXA4 in the induction of macrophage death. *Journal of Experimental*
1219 *Medicine* 205, 2791-2801.
- 1220 Chiurchiù, V., Leuti, A., and Maccarrone, M. (2018). Bioactive Lipids and Chronic
1221 Inflammation: Managing the Fire Within. *Frontiers in Immunology* 9.
- 1222 Clipet-Jensen, C., Andersen, A., Jensen, A.K.G., Aaby, P., and Zaman, K. (2021). Out-of-
1223 Sequence Vaccinations With Measles Vaccine and Diphtheria-Tetanus-Pertussis Vaccine: A
1224 Reanalysis of Demographic Surveillance Data From Rural Bangladesh. *Clin Infect Dis* 72, 1429-
1225 1436.
- 1226 Comstock, G.W. (1988). Identification of an effective vaccine against tuberculosis. *Am Rev*
1227 *Respir Dis* 138, 479-480.
- 1228 Conti, M.G., Angelidou, A., Diray-Arce, J., Smolen, K.K., Lasky-Su, J., De Curtis, M., and
1229 Levy, O. (2020). Immunometabolic approaches to prevent, detect, and treat neonatal sepsis.
1230 *Pediatr Res* 87, 399-405.
- 1231 Curtis, N., Sparrow, A., Ghebreyesus, T.A., and Netea, M.G. (2020). Considering BCG
1232 vaccination to reduce the impact of COVID-19. *Lancet*.
- 1233 Dela Pena-Ponce, M.G., Rodriguez-Nieves, J., Bernhardt, J., Tuck, R., Choudhary, N., Mengual,
1234 M., Mollan, K.R., Hudgens, M.G., Peter-Wohl, S., and De Paris, K. (2017). Increasing
1235 JAK/STAT Signaling Function of Infant CD4(+) T Cells during the First Year of Life. *Front*
1236 *Pediatr* 5, 15.
- 1237 Diray-Arce, J., Conti, M.G., Petrova, B., Kanarek, N., Angelidou, A., and Levy, O. (2020).
1238 Integrative Metabolomics to Identify Molecular Signatures of Responses to Vaccines and
1239 Infections. *Metabolites* 10.
- 1240 Diray-Arce, J., Miller, H.E.R., Henrich, E., Gerritsen, B., Mulè, M.P., Fourati, S., Gygi, J.,
1241 Hagan, T., Tomalin, L., Rychkov, D., *et al.* (2021). The Immune Signatures Data Resource: A
1242 compendium of systems vaccinology datasets. *bioRxiv*, 2021.2011.2005.465336.
- 1243 Dowling, D.J., and Levy, O. (2014). Ontogeny of early life immunity. *Trends Immunol* 35, 299-
1244 310.
- 1245 Evans, A.M., DeHaven, C.D., Barrett, T., Mitchell, M., and Milgram, E. (2009). Integrated,
1246 Nontargeted Ultrahigh Performance Liquid Chromatography/Electrospray Ionization Tandem
1247 Mass Spectrometry Platform for the Identification and Relative Quantification of the Small-
1248 Molecule Complement of Biological Systems. *Analytical Chemistry* 81, 6656-6667.
- 1249 Fanos, V., Atzori, L., Makarenko, K., Melis, G.B., and Ferrazzi, E. (2013). Metabolomics
1250 application in maternal-fetal medicine. *Biomed Res Int* 2013, 720514.
- 1251 Faustman, D.L. (2020). Benefits of BCG-induced metabolic switch from oxidative
1252 phosphorylation to aerobic glycolysis in autoimmune and nervous system diseases. *J Intern Med*.
- 1253 Fok, E.T., Davignon, L., Fanucchi, S., and Mhlanga, M.M. (2019). The lncRNA Connection
1254 Between Cellular Metabolism and Epigenetics in Trained Immunity. *Frontiers in Immunology* 9.
- 1255 Freyne, B., Donath, S., Germano, S., Gardiner, K., Casalez, D., Robins-Browne, R.M.,
1256 Amenogbe, N., Messina, N.L., Netea, M.G., Flanagan, K.L., *et al.* (2018). Neonatal BCG




- 1257 Vaccination Influences Cytokine Responses to Toll-like Receptor Ligands and Heterologous
1258 Antigens. *J Infect Dis* 217, 1798-1808.
- 1259 Guijas, C., Montenegro-Burke, J.R., Warth, B., Spilker, M.E., and Siuzdak, G. (2018).
1260 Metabolomics activity screening for identifying metabolites that modulate phenotype. *Nature*
1261 *Biotechnology* 36, 316-320.
- 1262 Haahr, S., Michelsen, S.W., Andersson, M., Bjorn-Mortensen, K., Soborg, B., Wohlfahrt, J.,
1263 Melbye, M., and Koch, A. (2016). Non-specific effects of BCG vaccination on morbidity among
1264 children in Greenland: a population-based cohort study. *Int J Epidemiol* 45, 2122-2130.
- 1265 Hagan, T., Nakaya, H.I., Subramaniam, S., and Pulendran, B. (2015). Systems vaccinology:
1266 Enabling rational vaccine design with systems biological approaches. *Vaccine* 33, 5294-5301.
- 1267 Higgins, J.P., Soares-Weiser, K., Lopez-Lopez, J.A., Kakourou, A., Chaplin, K., Christensen, H.,
1268 Martin, N.K., Sterne, J.A., and Reingold, A.L. (2016). Association of BCG, DTP, and measles
1269 containing vaccines with childhood mortality: systematic review. *BMJ* 355, i5170.
- 1270 Jensen, K.J., Larsen, N., Biering-Sorensen, S., Andersen, A., Eriksen, H.B., Monteiro, I.,
1271 Hougaard, D., Aaby, P., Netea, M.G., Flanagan, K.L., *et al.* (2015). Heterologous immunological
1272 effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-
1273 controlled trial. *J Infect Dis* 211, 956-967.
- 1274 Jia, P., Wang, Q., Chen, Q., Hutchinson, K.E., Pao, W., and Zhao, Z. (2014). MSEA: detection
1275 and quantification of mutation hotspots through mutation set enrichment analysis. *Genome Biol*
1276 15, 489.
- 1277 Johnson, C.H., Ivanisevic, J., and Siuzdak, G. (2016). Metabolomics: beyond biomarkers and
1278 towards mechanisms. *Nature Reviews Molecular Cell Biology* 17, 451-459.
- 1279 Kan, B., Michalski, C., Fu, H., Au, H.H.T., Lee, K., Marchant, E.A., Cheng, M.F., Anderson-
1280 Baucum, E., Aharoni-Simon, M., Tilley, P., *et al.* (2018). Cellular metabolism constrains innate
1281 immune responses in early human ontogeny. *Nat Commun* 9, 4822.
- 1282 Kelly, B., and O'Neill, L.A. (2015). Metabolic reprogramming in macrophages and dendritic
1283 cells in innate immunity. *Cell Res* 25, 771-784.
- 1284 Kjaergaard, J., Birk, N.M., Nissen, T.N., Thostesen, L.M., Pihl, G.T., Benn, C.S., Jeppesen,
1285 D.L., Pryds, O., Kofoed, P.E., Aaby, P., *et al.* (2016). Nonspecific effect of BCG vaccination at
1286 birth on early childhood infections: a randomized, clinical multicenter trial. *Pediatr Res* 80, 681-
1287 685.
- 1288 Kleinnijenhuis, J., Quintin, J., Preijers, F., Joosten, L.A., Ifrim, D.C., Saeed, S., Jacobs, C., van
1289 Loenhout, J., de Jong, D., Stunnenberg, H.G., *et al.* (2012). Bacille Calmette-Guerin induces
1290 NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of
1291 monocytes. *Proc Natl Acad Sci U S A* 109, 17537-17542.
- 1292 Knuplez, E., and Marsche, G. (2020). An Updated Review of Pro- and Anti-Inflammatory
1293 Properties of Plasma Lysophosphatidylcholines in the Vascular System. *Int J Mol Sci* 21.
- 1294 Kollmann, T.R. (2013). Variation between Populations in the Innate Immune Response to
1295 Vaccine Adjuvants. *Front Immunol* 4, 81.
- 1296 Langley, R.J., Tsalik, E.L., van Velkinburgh, J.C., Glickman, S.W., Rice, B.J., Wang, C., Chen,
1297 B., Carin, L., Suarez, A., Mohny, R.P., *et al.* (2013). An integrated clinico-metabolomic model
1298 improves prediction of death in sepsis. *Sci Transl Med* 5, 195ra195.
- 1299 Law, S.H., Chan, M.L., Marathe, G.K., Parveen, F., Chen, C.H., and Ke, L.Y. (2019). An
1300 Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases. *Int J Mol Sci* 20.

- 1301 Lawton, K.A., Berger, A., Mitchell, M., Milgram, K.E., Evans, A.M., Guo, L., Hanson, R.W.,
1302 Kalhan, S.C., Ryals, J.A., and Milburn, M.V. (2008). Analysis of the adult human plasma
1303 metabolome. *Pharmacogenomics* 9, 383-397.
- 1304 Lee, A.H., Shannon, C.P., Amenyogbe, N., Bennike, T.B., Diray-Arce, J., Idoko, O.T., Gill,
1305 E.E., Ben-Othman, R., Pomat, W.S., van Haren, S.D., *et al.* (2019). Dynamic molecular changes
1306 during the first week of human life follow a robust developmental trajectory. *Nat Commun* 10,
1307 1092.
- 1308 Lee, H.-J., Ko, H.-J., Song, D.-K., and Jung, Y.-J. (2018). Lysophosphatidylcholine Promotes
1309 Phagosome Maturation and Regulates Inflammatory Mediator Production Through the Protein
1310 Kinase A–Phosphatidylinositol 3–Kinase–p38 Mitogen-Activated Protein Kinase Signaling
1311 Pathway During Mycobacterium tuberculosis Infection in Mouse Macrophages. *Frontiers in*
1312 *Immunology* 9.
- 1313 Li, S., Sullivan, N.L., Roupheal, N., Yu, T., Banton, S., Maddur, M.S., McCausland, M., Chiu,
1314 C., Canniff, J., Dubey, S., *et al.* (2017). Metabolic Phenotypes of Response to Vaccination in
1315 Humans. *Cell* 169, 862-877 e817.
- 1316 Li, Z., Xie, Y., Xiao, Q., and Wang, L. (2020). Terminal osseous dysplasia with pigmentary
1317 defects in a Chinese girl with the FLNA mutation: A case report and published work review. *J*
1318 *Dermatol* 47, 295-299.
- 1319 Libraty, D.H., Zhang, L., Woda, M., Acosta, L.P., Obcena, A., Brion, J.D., and Capeding, R.Z.
1320 (2014). Neonatal BCG vaccination is associated with enhanced T-helper 1 immune responses to
1321 heterologous infant vaccines. *Trials Vaccinol* 3, 1-5.
- 1322 Lochner, M., Berod, L., and Sparwasser, T. (2015). Fatty acid metabolism in the regulation of T
1323 cell function. *Trends Immunol* 36, 81-91.
- 1324 Lofgren, L., Stahlman, M., Forsberg, G.B., Saarinen, S., Nilsson, R., and Hansson, G.I. (2012).
1325 The BUMe method: a novel automated chloroform-free 96-well total lipid extraction method for
1326 blood plasma. *J Lipid Res* 53, 1690-1700.
- 1327 Long, T., Hicks, M., Yu, H.C., Biggs, W.H., Kirkness, E.F., Menni, C., Zierer, J., Small, K.S.,
1328 Mangino, M., Messier, H., *et al.* (2017). Whole-genome sequencing identifies common-to-rare
1329 variants associated with human blood metabolites. *Nat Genet* 49, 568-578.
- 1330 Lund, N., Andersen, A., Hansen, A.S., Jepsen, F.S., Barbosa, A., Biering-Sorensen, S.,
1331 Rodrigues, A., Ravn, H., Aaby, P., and Benn, C.S. (2015). The Effect of Oral Polio Vaccine at
1332 Birth on Infant Mortality: A Randomized Trial. *Clin Infect Dis* 61, 1504-1511.
- 1333 Marchant, A., Goetghebuer, T., Ota, M.O., Wolfe, I., Ceesay, S.J., De Groote, D., Corrah, T.,
1334 Bennett, S., Wheeler, J., Huygen, K., *et al.* (1999). Newborns develop a Th1-type immune
1335 response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. *J Immunol* 163, 2249-
1336 2255.
- 1337 McFarland, C.T., Fan, Y.Y., Chapkin, R.S., Weeks, B.R., and McMurray, D.N. (2008). Dietary
1338 polyunsaturated fatty acids modulate resistance to Mycobacterium tuberculosis in guinea pigs. *J*
1339 *Nutr* 138, 2123-2128.
- 1340 Members, M.S.I.B., Sansone, S.A., Fan, T., Goodacre, R., Griffin, J.L., Hardy, N.W., Kaddurah-
1341 Daouk, R., Kristal, B.S., Lindon, J., Mendes, P., *et al.* (2007). The metabolomics standards
1342 initiative. *Nat Biotechnol* 25, 846-848.
- 1343 Moorlag, S., Arts, R.J.W., van Crevel, R., and Netea, M.G. (2019). Non-specific effects of BCG
1344 vaccine on viral infections. *Clin Microbiol Infect* 25, 1473-1478.
- 1345 Moorlag, S., van Deuren, R.C., van Werkhoven, C.H., Jaeger, M., Debisarun, P., Taks, E.,
1346 Mourits, V.P., Koeken, V., de Bree, L.C.J., Ten Doesschate, T., *et al.* (2020). Safety and

- 1347 COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort
1348 Study. *Cell Rep Med* 1, 100073.
- 1349 Mussap, M., Antonucci, R., Noto, A., and Fanos, V. (2013). The role of metabolomics in
1350 neonatal and pediatric laboratory medicine. *Clin Chim Acta* 426, 127-138.
- 1351 Nakaya, H.I., Clutterbuck, E., Kazmin, D., Wang, L., Cortese, M., Bosinger, S.E., Patel, N.B.,
1352 Zak, D.E., Aderem, A., Dong, T., *et al.* (2016). Systems biology of immunity to MF59-
1353 adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. *Proc*
1354 *Natl Acad Sci U S A* 113, 1853-1858.
- 1355 Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means,
1356 A.R., Kasturi, S.P., Khan, N., Li, G.M., *et al.* (2011). Systems biology of vaccination for
1357 seasonal influenza in humans. *Nat Immunol* 12, 786-795.
- 1358 Netea, M.G., Joosten, L.A., Latz, E., Mills, K.H., Natoli, G., Stunnenberg, H.G., O'Neill, L.A.,
1359 and Xavier, R.J. (2016). Trained immunity: A program of innate immune memory in health and
1360 disease. *Science* 352, aaf1098.
- 1361 O'Neill, L.A., Kishton, R.J., and Rathmell, J. (2016). A guide to immunometabolism for
1362 immunologists. *Nat Rev Immunol* 16, 553-565.
- 1363 Ojala, P.J., Hirvonen, T.E., Hermansson, M., Somerharju, P., and Parkkinen, J. (2007). Acyl
1364 chain-dependent effect of lysophosphatidylcholine on human neutrophils. *J Leukoc Biol* 82,
1365 1501-1509.
- 1366 Okita, M., Gaudette, D.C., Mills, G.B., and Holub, B.J. (1997). Elevated levels and altered fatty
1367 acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. *Int J*
1368 *Cancer* 71, 31-34.
- 1369 Perrin-Cocon, L., Agaogue, S., Coutant, F., Saint-Mezard, P., Guironnet-Paquet, A., Nicolas,
1370 J.F., Andre, P., and Lotteau, V. (2006). Lysophosphatidylcholine is a natural adjuvant that
1371 initiates cellular immune responses. *Vaccine* 24, 1254-1263.
- 1372 Petrick, L.M., Schiffman, C., Edmands, W.M.B., Yano, Y., Perttula, K., Whitehead, T., Metayer,
1373 C., Wheelock, C.E., Arora, M., Grigoryan, H., *et al.* (2019). Metabolomics of neonatal blood
1374 spots reveal distinct phenotypes of pediatric acute lymphoblastic leukemia and potential effects
1375 of early-life nutrition. *Cancer Lett* 452, 71-78.
- 1376 Pettengill, M.A., van Haren, S.D., and Levy, O. (2014). Soluble mediators regulating immunity
1377 in early life. *Front Immunol* 5, 457.
- 1378 Playdon, M.C., Ziegler, R.G., Sampson, J.N., Stolzenberg-Solomon, R., Thompson, H.J., Irwin,
1379 M.L., Mayne, S.T., Hoover, R.N., and Moore, S.C. (2017). Nutritional metabolomics and breast
1380 cancer risk in a prospective study. *Am J Clin Nutr* 106, 637-649.
- 1381 Prentice, S., Nassanga, B., Webb, E.L., Akello, F., Kiwudhu, F., Akurut, H., Elliott, A.M., Arts,
1382 R.J.W., Netea, M.G., Dockrell, H.M., *et al.* (2021). BCG-induced non-specific effects on
1383 heterologous infectious disease in Ugandan neonates: an investigator-blind randomised
1384 controlled trial. *Lancet Infect Dis* 21, 993-1003.
- 1385 Reinke, S.N., Walsh, B.H., Boylan, G.B., Sykes, B.D., Kenny, L.C., Murray, D.M., and
1386 Broadhurst, D.I. (2013). ¹H NMR derived metabolomic profile of neonatal asphyxia in umbilical
1387 cord serum: implications for hypoxic ischemic encephalopathy. *J Proteome Res* 12, 4230-4239.
- 1388 Rothman, K.J. (1990). No Adjustments Are Needed for Multiple Comparisons. *Epidemiology* 1,
1389 43-46.
- 1390 Sanchez-Schmitz, G., and Levy, O. (2011). Development of newborn and infant vaccines. *Sci*
1391 *Transl Med* 3, 90ps27.


- 1392 Sanchez-Schmitz, G., Stevens, C.R., Bettencourt, I.A., Flynn, P.J., Schmitz-Abe, K., Metser, G.,
1393 Hamm, D., Jensen, K.J., Benn, C., and Levy, O. (2018). Microphysiologic Human Tissue
1394 Constructs Reproduce Autologous Age-Specific BCG and HBV Primary Immunization in vitro.
1395 *Front Immunol* 9, 2634.
- 1396 Scheid, A., Borriello, F., Pietrasanta, C., Christou, H., Diray-Arce, J., Pettengill, M.A., Joshi, S.,
1397 Li, N., Bergelson, I., Kollmann, T., *et al.* (2018). Adjuvant Effect of Bacille Calmette-Guerin on
1398 Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn. *Front Immunol* 9, 29.
- 1399 Sharma, N., Akhade, A.S., Ismaeel, S., and Qadri, A. (2020). Serum-borne lipids amplify TLR-
1400 activated inflammatory responses. *J Leukoc Biol.*
- 1401 Skogstrand, K., Thorsen, P., Norgaard-Pedersen, B., Schendel, D.E., Sorensen, L.C., and
1402 Hougaard, D.M. (2005). Simultaneous measurement of 25 inflammatory markers and
1403 neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. *Clin Chem*
1404 *51*, 1854-1866.
- 1405 Soehnlein, O., Lindbom, L., and Weber, C. (2009). Mechanisms underlying neutrophil-mediated
1406 monocyte recruitment. *Blood* *114*, 4613-4623.
- 1407 Sorup, S., Benn, C.S., Poulsen, A., Krause, T.G., Aaby, P., and Ravn, H. (2016). Simultaneous
1408 vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections:
1409 A nationwide register based cohort study. *Vaccine* *34*, 6172-6180.
- 1410 Spicer, R.A., Salek, R., and Steinbeck, C. (2017). A decade after the metabolomics standards
1411 initiative it's time for a revision. *Sci Data* *4*, 170138.
- 1412 Stenzen, J.A., and Poschenrieder, A.J. (2015). Bioanalytical chemistry of cytokines--a review.
1413 *Anal Chim Acta* *853*, 95-115.
- 1414 Sumner, L.W., Amberg, A., Barrett, D., Beale, M.H., Berger, R., Daykin, C.A., Fan, T.W., Fiehn,
1415 O., Goodacre, R., Griffin, J.L., *et al.* (2007). Proposed minimum reporting standards for
1416 chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards
1417 Initiative (MSI). *Metabolomics* *3*, 211-221.
- 1418 Thyssen, S.M., Rodrigues, A., Aaby, P., and Fisker, A.B. (2019). Out-of-sequence DTP and
1419 measles vaccinations and child mortality in Guinea-Bissau: a reanalysis. *BMJ Open* *9*, e024893.
- 1420 Uhl, O., Fleddermann, M., Hellmuth, C., Demmelmair, H., and Koletzko, B. (2016).
1421 Phospholipid Species in Newborn and 4 Month Old Infants after Consumption of Different
1422 Formulas or Breast Milk. *PLoS one* *11*, e0162040.
- 1423 Welaga, P., Oduro, A., Debpuur, C., Aaby, P., Ravn, H., Andersen, A., Binka, F., and Hodgson,
1424 A. (2017). Fewer out-of-sequence vaccinations and reduction of child mortality in Northern
1425 Ghana. *Vaccine* *35*, 2496-2503.
- 1426 White, O.J., McKenna, K.L., Bosco, A., A, H.J.v.d.B., Richmond, P., and Holt, P.G. (2012). A
1427 genomics-based approach to assessment of vaccine safety and immunogenicity in children.
1428 *Vaccine* *30*, 1865-1874.
- 1429 Whittaker, E., Goldblatt, D., McIntyre, P., and Levy, O. (2018). Neonatal Immunization:
1430 Rationale, Current State, and Future Prospects. *Front Immunol* *9*, 532.
- 1431 World Health, O. (2020). Children: Improving Survival and Well-being.
- 1432 Xia, J., Sinelnikov, I.V., Han, B., and Wishart, D.S. (2015). MetaboAnalyst 3.0--making
1433 metabolomics more meaningful. *Nucleic Acids Res* *43*, W251-257.
- 1434 Xia, J., and Wishart, D.S. (2011). Metabolomic data processing, analysis, and interpretation
1435 using MetaboAnalyst. *Curr Protoc Bioinformatics Chapter 14*, Unit 14 10.
- 1436 Xia, J., and Wishart, D.S. (2016). Using MetaboAnalyst 3.0 for Comprehensive Metabolomics
1437 Data Analysis. *Curr Protoc Bioinformatics* *55*, 14 10 11-14 10 91.

1438 Yan, J.-J., Jung, J.-S., Lee, J.-E., Lee, J., Huh, S.-O., Kim, H.-S., Jung, K.C., Cho, J.-Y., Nam, J.-
1439 S., Suh, H.-W., *et al.* (2004). Therapeutic effects of lysophosphatidylcholine in experimental
1440 sepsis. *Nature Medicine* *10*, 161-167.
1441 Zimmermann, P., Donath, S., Perrett, K.P., Messina, N.L., Ritz, N., Netea, M.G., Flanagan, K.L.,
1442 van der Klis, F.R.M., Curtis, N., and group, M.B. (2019). The influence of neonatal Bacille
1443 Calmette-Guerin (BCG) immunisation on heterologous vaccine responses in infants. *Vaccine* *37*,
1444 3735-3744.
1445
1446




**Metabolic changes
induced by BCG vaccine**


A In Vivo Assay: Guinea-Bissau Cohort







B In Vitro Assay: Boston Cohort



C Validation Cohort: EPIC-001 Gambia pilot cohort



A**In vivo sampling procedures****B****C****Top 35 Loadings (Early BCG vs Delayed BCG)****D****E**